,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2018', 'fs': 'Aug 2018', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006tsa6UAA'}, 'Id': 'a0P2P000006tsa6UAA', 'Event_Date__c': '2018-08-09', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Aug 2018', 'Status_History__c': 'a132P000000ArV7QAK'}, 'change': None}]",Aug 2018,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2018', 'fs': 'Sep 2018', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006tsa7UAA'}, 'Id': 'a0P2P000006tsa7UAA', 'Event_Date__c': '2018-09-07', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Sep 2018', 'Status_History__c': 'a132P000000ArXEQA0'}, 'change': None}, {'Summary': {'s': 'The Subcommittee recommended that nusinersen for the treatment of spinal muscular atrophy type II and IIIa be deferred until longer-term follow-up analyses are published from the SHINE and/or NURTURE trials.', 'fs': 'The Subcommittee recommended that nusinersen for the treatment of spinal muscular atrophy type II and IIIa be deferred until longer-term follow-up analyses are published from the SHINE and/or NURTURE trials.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Deferred', 'fs': 'Deferred', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-rare-disorders-subcommittee-minutes-2018-11.pdf"" target=""_blank"">Rare Disorders Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-rare-disorders-subcommittee-minutes-2018-11.pdf"" target=""_blank"">Rare Disorders Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Nov 2018', 'fs': 'Nov 2018', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Rare Disorders Subcommittee at meeting Monday 5 November 2018.', 'fs': 'Clinical advice received from Rare Disorders Subcommittee at meeting Monday 5 November 2018.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006tsa8UAA'}, 'Id': 'a0P2P000006tsa8UAA', 'Event_Date__c': '2018-11-05', 'Event_Description__c': 'Clinical advice received from Rare Disorders Subcommittee at meeting Monday 5 November 2018.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-rare-disorders-subcommittee-minutes-2018-11.pdf"" target=""_blank"">Rare Disorders Subcommittee minutes</a>', 'Outcome__c': 'Deferred', 'Summary__c': 'The Subcommittee recommended that nusinersen for the treatment of spinal muscular atrophy type II and IIIa be deferred until longer-term follow-up analyses are published from the SHINE and/or NURTURE trials.', 'Formatted_Date__c': 'Nov 2018', 'Status_History__c': 'a132P000000ArZEQA0'}, 'change': None}, {'Summary': {'s': 'The Subcommittee minutes will be considered at the February 2019 PTAC meeting.', 'fs': 'The Subcommittee minutes will be considered at the February 2019 PTAC meeting.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2019', 'fs': 'Feb 2019', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006tsa9UAA'}, 'Id': 'a0P2P000006tsa9UAA', 'Event_Date__c': '2019-02-21', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Summary__c': 'The Subcommittee minutes will be considered at the February 2019 PTAC meeting.', 'Formatted_Date__c': 'Feb 2019', 'Status_History__c': 'a132P000000Arb2QAC'}, 'change': None}, {'Summary': {'s': 'The Committee noted and accepted the Subcommittee recommendations to defer consideration of nusinersen for spinal muscular atrophy type I, type II and IIIa until longer-term follow-up analyses are published from the SHINE and NURTURE trials.  The Committee recommended that consideration of interim analyses of the key nusinersen trials (NURTURE and SHINE) should be delegated to the Rare Disorders Subcommittee and the Subcommittee could then consider if this data was sufficiently mature enough to be brought back to PTAC.', 'fs': 'The Committee noted and accepted the Subcommittee recommendations to defer consideration of nusinersen for spinal muscular atrophy type I, type II and IIIa until longer-term follow-up analyses are published from the SHINE and NURTURE trials.  The Committee recommended that consideration of interim analyses of the key nusinersen trials (NURTURE and SHINE) should be delegated to the Rare Disorders Subcommittee and the Subcommittee could then consider if this data was sufficiently mature enough to be brought back to PTAC.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Deferred', 'fs': 'Deferred', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2019-02.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2019-02.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'May 2019', 'fs': 'May 2019', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 23 May 2019.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 23 May 2019.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006tsaAUAQ'}, 'Id': 'a0P2P000006tsaAUAQ', 'Event_Date__c': '2019-05-23', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 23 May 2019.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2019-02.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Deferred', 'Summary__c': 'The Committee noted and accepted the Subcommittee recommendations to defer consideration of nusinersen for spinal muscular atrophy type I, type II and IIIa until longer-term follow-up analyses are published from the SHINE and NURTURE trials.  The Committee recommended that consideration of interim analyses of the key nusinersen trials (NURTURE and SHINE) should be delegated to the Rare Disorders Subcommittee and the Subcommittee could then consider if this data was sufficiently mature enough to be brought back to PTAC.', 'Formatted_Date__c': 'May 2019', 'Status_History__c': 'a132P000000ArfxQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2019', 'fs': 'Aug 2019', 'change': None}, 'Event_Description': {'s': 'Received Additional Information', 'fs': 'Received Additional Information', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006tsaBUAQ'}, 'Id': 'a0P2P000006tsaBUAQ', 'Event_Date__c': '2019-08-05', 'Event_Description__c': 'Received Additional Information', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Aug 2019', 'Status_History__c': 'a132P000000ArhrQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2019', 'fs': 'Sep 2019', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006tsaCUAQ'}, 'Id': 'a0P2P000006tsaCUAQ', 'Event_Date__c': '2019-09-17', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Sep 2019', 'Status_History__c': 'a132P000000B3RjQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> nusinersen be funded with a <b>high</b> priority, within the context of the rare disorders therapeutic area, for the treatment of pre-symptomatic individuals with spinal muscular atrophy and two or three <i>SMN2 </i>copies, subject to the Special Authority criteria below. This recommendation was<i> </i>based on the absence of funded alternatives, the high health need of these individuals and their family/whānau, longer-term evidence of survival gain and meaningful clinical benefit with nusinersen, and that patients with pre-symptomatic SMA had the greatest potential to benefit.</p><p>\t<b style=""font-size: 9pt;"">Initiation – spinal muscular atrophy (SMA) – pre-symptomatic</b></p><p><span style=""font-size: 9pt;"">Applications only from, or in consultation with, a specialist medical practitioner experienced in the diagnosis and management of SMA associated with a neuromuscular clinic of a recognised hospital in the management of SMA.</span></p><p><span style=""font-size: 9pt;"">Re-assessment required after 12 </span><span style=""font-size: 9pt; color: black;"">months</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Genetic documentation of 5q SMA homozygous gene deletion, homozygous mutation, or compound heterozygous mutation, </span><span style=""font-size: 9pt; color: black;"">identified via newborn screening; </span><span style=""font-size: 9pt;"">and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient must be pre-symptomatic; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient must have only two or three copies of </span><i style=""font-size: 9pt;"">SMN2</i><span style=""font-size: 9pt;"">; and</span></p><p><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment must be given concomitantly with standard of care for this condition; and</span></p><p><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment must not exceed four loading doses (at days 0, 14, 28 and 63); and</span></p><p><span style=""font-size: 9pt;"">6.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient must be 18 years of age or under.</span></p><p><br></p><p><span style=""font-size: 9pt;"">Continuation – spinal muscular atrophy (SMA) – pre-symptomatic</span></p><p><span style=""font-size: 9pt;"">Applications only from, or in consultation with, a specialist medical practitioner experienced in the diagnosis and management of SMA associated with a neuromuscular clinic of a recognised hospital in the management of SMA.</span></p><p><span style=""font-size: 9pt;"">Re-assessment required after 12 months</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient must have had a previous approval for nusinersen; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment must be given concomitantly with standard of care for this condition; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">There has been demonstrated maintenance of motor milestone function (as assessed using age-appropriate scales: the HINE Section 2, CHOP INTEND, or HFMSE) since treatment initiation; and</span></p><p><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The patient does not require invasive permanent assisted ventilation (see Note).</span></p><p><br></p><p><span style=""font-size: 9pt;"">Note: </span></p><p><u style=""font-size: 9pt;"">Invasive permanent assisted ventilation means:</u></p><p><span style=""font-size: 9pt;"">Ventilation via tracheostomy tube for greater than or equal to 16 hours per day.</span></p><p>\xa0</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> nusinersen be funded with a <b>medium</b> priority, within the context of the rare disorders therapeutic area, for the treatment of symptomatic patients with type I, II, and IIIa spinal muscular atrophy, subject to the Special Authority criteria below. This recommendation was based on the absence of funded alternatives, the high health need of these individuals and their family/whānau, evidence of survival gain for infantile onset SMA and meaningful clinical benefit for all symptomatic subgroups considered.</p><p>\t<b style=""font-size: 9pt;"">Initiation – spinal muscular atrophy (SMA) – symptomatic type I, II and IIIa</b></p><p>\t</p><p><span style=""font-size: 9pt;"">Applications only from or in consultation with a specialist medical practitioner experienced in the diagnosis and management of SMA associated with a neuromuscular clinic of a recognised hospital in the management of SMA.</span></p><p><br></p><p><span style=""font-size: 9pt;"">Re-assessment required after 12 months</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Genetic documentation of 5q SMA homozygous gene deletion, homozygous mutation, or compound heterozygous mutation; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient must have experienced the defined signs and symptoms of SMA type I, II or IIIa prior to 3 years of age (see Notes); and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment must be given concomitantly with standard of care for this condition; and</span></p><p><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment must not exceed four loading doses (at days 0, 14, 28 and 63); and</span></p><p><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient must be 18 years of age or under.</span></p><p><br></p><p><span style=""font-size: 9pt;"">Continuation – spinal muscular atrophy (SMA) – symptomatic type I, II and IIIa</span></p><p><span style=""font-size: 9pt;"">Applications only from, or in consultation with a specialist medical practitioner experienced in the diagnosis and management of SMA associated with a neuromuscular clinic of a recognised hospital in the management of SMA.</span></p><p><span style=""font-size: 9pt;"">Re-assessment required after 12 months</span></p><p><br></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient must have had a previous approval for nusinersen; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment must be given concomitantly with standard of care for this condition; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">There has been demonstrated maintenance of motor milestone function (as assessed using age-appropriate scales: the HINE Section 2, CHOP INTEND, or HFMSE) since treatment initiation; and</span></p><p><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment must be ceased when invasive permanent assisted ventilation (see Note) is required in the absence of a potentially reversible cause while being treated with this drug.</span></p><p><br></p><p><span style=""font-size: 9pt;"">Notes: </span></p><p><u style=""font-size: 9pt;"">Invasive permanent assisted ventilation means:</u></p><p><span style=""font-size: 9pt;"">Ventilation via tracheostomy tube for greater than or equal to 16 hours per day.</span></p><p>\xa0</p><p><u style=""font-family: Arial, sans-serif; font-size: 9pt;"">Defined signs and symptoms of type I SMA are:</u></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">i) Onset before 6 months of age; and</span></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">ii) Failure to meet or regression in ability to perform age-appropriate motor milestones.</span></p><p><br></p><p><u style=""font-family: Arial, sans-serif; font-size: 9pt;"">Defined signs and symptoms of type II SMA are:</u></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">i) Onset between 6 and 18 months; and</span></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">ii) Failure to meet or regression in ability to perform age-appropriate motor milestones.</span></p><p><br></p><p><u style=""font-family: Arial, sans-serif; font-size: 9pt;"">Defined signs and symptoms of type IIIa SMA are:</u></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">i) Onset between 18 months and 3 years of age; and</span></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">ii) Failure to meet or regression in ability to perform age-appropriate motor milestones.</span></p>', 'fs': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> nusinersen be funded with a <b>high</b> priority, within the context of the rare disorders therapeutic area, for the treatment of pre-symptomatic individuals with spinal muscular atrophy and two or three <i>SMN2 </i>copies, subject to the Special Authority criteria below. This recommendation was<i> </i>based on the absence of funded alternatives, the high health need of these individuals and their family/whānau, longer-term evidence of survival gain and meaningful clinical benefit with nusinersen, and that patients with pre-symptomatic SMA had the greatest potential to benefit.</p><p>\t<b style=""font-size: 9pt;"">Initiation – spinal muscular atrophy (SMA) – pre-symptomatic</b></p><p><span style=""font-size: 9pt;"">Applications only from, or in consultation with, a specialist medical practitioner experienced in the diagnosis and management of SMA associated with a neuromuscular clinic of a recognised hospital in the management of SMA.</span></p><p><span style=""font-size: 9pt;"">Re-assessment required after 12 </span><span style=""font-size: 9pt; color: black;"">months</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Genetic documentation of 5q SMA homozygous gene deletion, homozygous mutation, or compound heterozygous mutation, </span><span style=""font-size: 9pt; color: black;"">identified via newborn screening; </span><span style=""font-size: 9pt;"">and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient must be pre-symptomatic; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient must have only two or three copies of </span><i style=""font-size: 9pt;"">SMN2</i><span style=""font-size: 9pt;"">; and</span></p><p><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment must be given concomitantly with standard of care for this condition; and</span></p><p><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment must not exceed four loading doses (at days 0, 14, 28 and 63); and</span></p><p><span style=""font-size: 9pt;"">6.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient must be 18 years of age or under.</span></p><p><br></p><p><span style=""font-size: 9pt;"">Continuation – spinal muscular atrophy (SMA) – pre-symptomatic</span></p><p><span style=""font-size: 9pt;"">Applications only from, or in consultation with, a specialist medical practitioner experienced in the diagnosis and management of SMA associated with a neuromuscular clinic of a recognised hospital in the management of SMA.</span></p><p><span style=""font-size: 9pt;"">Re-assessment required after 12 months</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient must have had a previous approval for nusinersen; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment must be given concomitantly with standard of care for this condition; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">There has been demonstrated maintenance of motor milestone function (as assessed using age-appropriate scales: the HINE Section 2, CHOP INTEND, or HFMSE) since treatment initiation; and</span></p><p><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The patient does not require invasive permanent assisted ventilation (see Note).</span></p><p><br></p><p><span style=""font-size: 9pt;"">Note: </span></p><p><u style=""font-size: 9pt;"">Invasive permanent assisted ventilation means:</u></p><p><span style=""font-size: 9pt;"">Ventilation via tracheostomy tube for greater than or equal to 16 hours per day.</span></p><p>\xa0</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> nusinersen be funded with a <b>medium</b> priority, within the context of the rare disorders therapeutic area, for the treatment of symptomatic patients with type I, II, and IIIa spinal muscular atrophy, subject to the Special Authority criteria below. This recommendation was based on the absence of funded alternatives, the high health need of these individuals and their family/whānau, evidence of survival gain for infantile onset SMA and meaningful clinical benefit for all symptomatic subgroups considered.</p><p>\t<b style=""font-size: 9pt;"">Initiation – spinal muscular atrophy (SMA) – symptomatic type I, II and IIIa</b></p><p>\t</p><p><span style=""font-size: 9pt;"">Applications only from or in consultation with a specialist medical practitioner experienced in the diagnosis and management of SMA associated with a neuromuscular clinic of a recognised hospital in the management of SMA.</span></p><p><br></p><p><span style=""font-size: 9pt;"">Re-assessment required after 12 months</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Genetic documentation of 5q SMA homozygous gene deletion, homozygous mutation, or compound heterozygous mutation; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient must have experienced the defined signs and symptoms of SMA type I, II or IIIa prior to 3 years of age (see Notes); and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment must be given concomitantly with standard of care for this condition; and</span></p><p><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment must not exceed four loading doses (at days 0, 14, 28 and 63); and</span></p><p><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient must be 18 years of age or under.</span></p><p><br></p><p><span style=""font-size: 9pt;"">Continuation – spinal muscular atrophy (SMA) – symptomatic type I, II and IIIa</span></p><p><span style=""font-size: 9pt;"">Applications only from, or in consultation with a specialist medical practitioner experienced in the diagnosis and management of SMA associated with a neuromuscular clinic of a recognised hospital in the management of SMA.</span></p><p><span style=""font-size: 9pt;"">Re-assessment required after 12 months</span></p><p><br></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient must have had a previous approval for nusinersen; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment must be given concomitantly with standard of care for this condition; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">There has been demonstrated maintenance of motor milestone function (as assessed using age-appropriate scales: the HINE Section 2, CHOP INTEND, or HFMSE) since treatment initiation; and</span></p><p><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment must be ceased when invasive permanent assisted ventilation (see Note) is required in the absence of a potentially reversible cause while being treated with this drug.</span></p><p><br></p><p><span style=""font-size: 9pt;"">Notes: </span></p><p><u style=""font-size: 9pt;"">Invasive permanent assisted ventilation means:</u></p><p><span style=""font-size: 9pt;"">Ventilation via tracheostomy tube for greater than or equal to 16 hours per day.</span></p><p>\xa0</p><p><u style=""font-family: Arial, sans-serif; font-size: 9pt;"">Defined signs and symptoms of type I SMA are:</u></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">i) Onset before 6 months of age; and</span></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">ii) Failure to meet or regression in ability to perform age-appropriate motor milestones.</span></p><p><br></p><p><u style=""font-family: Arial, sans-serif; font-size: 9pt;"">Defined signs and symptoms of type II SMA are:</u></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">i) Onset between 6 and 18 months; and</span></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">ii) Failure to meet or regression in ability to perform age-appropriate motor milestones.</span></p><p><br></p><p><u style=""font-family: Arial, sans-serif; font-size: 9pt;"">Defined signs and symptoms of type IIIa SMA are:</u></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">i) Onset between 18 months and 3 years of age; and</span></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">ii) Failure to meet or regression in ability to perform age-appropriate motor milestones.</span></p>', 'change': None}, 'Published_Discussion': {'s': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that an application for nusinersen for the treatment of paediatric patients (18 years or under) with spinal muscular atrophy (SMA) types I, II, or IIIa with symptom onset before three years of age was considered by the Rare Disorders Subcommittee in <a href=""https://www.pharmac.govt.nz/assets/ptac-rare-disorders-subcommittee-minutes-2018-11.pdf"" target=""_blank"">November 2018</a>. At this time, the Subcommittee recommended that the application be deferred until longer-term follow-up data were published from the SHINE and/or NURTURE trials. PTAC subsequently reviewed the Record of the November 2018 Rare Disorders Subcommittee in <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2019-02.pdf"" target=""_blank"">February 2019</a>, and agreed with the Subcommittee’s recommendation to defer a decision on nusinersen until longer-term follow-up analyses were available. </p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that a resubmission for nusinersen was received by PHARMAC in August 2019 which included clarification of proposed eligibility criteria for nusinersen, longer-term data from the SHINE and NURTURE trials, and a revised price offer. The Subcommittee also considered correspondence regarding nusinersen received from a Paediatric Neurologist, Muscular Dystrophy New Zealand, and letters of support from the public.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the resubmission requested that the proposed eligibility criteria for nusinersen be widened from the original submission, which was for paediatric patients (18 years or under) with spinal muscular atrophy (SMA) types I, II, or IIIa with symptom onset before three years of age, to include pre-symptomatic individuals who have been genetically diagnosed with SMA.</p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee reviewed the aetiology and pathophysiology of SMA. The Subcommittee noted that SMA represents a continuous spectrum of phenotypes that are categorised into SMA type based on clinical manifestations (ie age of symptom onset and motor milestones achieved). </p><p><span style=""color: black;"">1.4.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted the point raised in the correspondence that individuals with SMA type IIIa do achieve the ability to walk, which differs from the definition described by the Rare Disorders Subcommittee in 2018 (individuals with SMA IIIa are predominantly non-ambulatory). The Subcommittee agreed with the correspondent, noting that individuals with SMA type IIIa do achieve the ability to walk; however, the Subcommittee also noted that these individuals have a high risk of losing this ability and becoming non-ambulatory during youth or adulthood. </p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the phenotypic severity and therefore the type of SMA is, at least in part, modified by the number of copies of the <i>SMN2</i> gene. The Subcommittee considered that, in general, individuals with one copy of <i>SMN2</i> develop SMA type\xa01a (also referred to as type 0, fatal in early infancy), individuals with two copies of <i>SMN2</i> develop SMA type Ib (feeding and respiratory problems, poor or no cephalic control), and individuals with three copies of <i>SMN2</i> can develop SMA of variable disease severity, ranging from type Ic (feeding and respiratory problems, some cephalic control) to SMA type V (ambulatory for normal life-span) (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/31053787"" target=""_blank"">Serra-Juhe &amp; Tizzano. Eur J Hum Genet. 2019; doi: 10.1038/s41431-019-0415-4. [Epub ahead of print]</a>). The Subcommittee noted that individuals with four or five copies of <i>SMN2</i> remain ambulatory and independent well into adulthood and have a normal lifespan. The Subcommittee considered that although it is not a perfect prognostic biomarker, the number of <i>SMN2</i> copies is the best phenotypic modifier of SMA identified to date.</p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that nusinersen is an antisense oligonucleotide therapy that modifies <i>SMN2</i> splicing allowing for translation of full-length SMN protein. The Subcommittee noted that nusinersen does not cure SMA but shifts the severity profile towards a milder disease phenotype.</p><p><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the resubmission included a description of the natural history of individuals with SMA type I and SMA type II and III gathered from published literature. The Subcommittee used these data as a point of comparison when considering the benefit reported for nusinersen in the pivotal trials. </p><p><span style=""color: black;"">1.8.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the resubmission included longer-term follow up data for patients with infantile-onset SMA (most likely to develop SMA type I) from the ENDEAR-SHINE study.</p><p><span style=""color: black;"">1.8.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that they had previously considered results from the ENDEAR-SHINE study after a median treatment duration of 528.6 days (30 June 2017 data cut). At the current meeting, the Subcommittee considered data from ENDEAR-SHINE after a median treatment duration of 987 days (15 October 2018 data cut); these results have not been published in a peer reviewed journal at this time, but were presented at the 2019 American Academy of Neurology Annual Meeting (<a href=""https://n.neurology.org/content/92/15_Supplement/S25.004"" target=""_blank"">Finkel et al. Interim Report on the Safety and Efficacy of Longer term Treatment with Nusinersen in Infantile onset Spinal Muscular Atrophy (SMA): Updated Results From the SHINE Study. Presented at: 2019 American Academy of Neurology Annual Meeting (AAN). May 4 to 10, 2019; Philadelphia, PA.</a>).</p><p><span style=""color: black;"">1.8.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted the results of the motor function assessments at the time of the October 2018 data cut of ENDEAR-SHINE, including change in CHOP INTEND (Children&#39;s Hospital of Philadelphia Infant Test of Neuromuscular Disorders) scores over time and WHO motor milestones. The Subcommittee considered that, in general, the results indicated a reversal of decline and further improvements in motor function over time with nusinersen treatment, and that greater improvements were observed when nusinersen treatment was initiated at a younger age. The Subcommittee noted that no statistical analyses were provided for these data, which limited the interpretation of the results at this stage.</p><p><span style=""color: black;"">1.8.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that 12 of the 24 patients who had received sham control in ENDEAR were alive and without permanent ventilation at baseline in SHINE, and that 7 of 12 of these infants were alive and without permanent ventilation at the time of the October 2018 data cut of ENDEAR-SHINE. The Subcommittee noted the Kaplan-Meier curve for time to death or permanent ventilation presented at the AAN meeting. The Subcommittee noted that the median time to event was 75 weeks in patients previously treated with nusinersen compared with 22.6 weeks for patients who had received the sham control.</p><p><span style=""color: black;"">1.8.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the safety profile was consistent with that previously reported in ENDEAR; the most frequent adverse events were pyrexia and upper respiratory tract infection. </p><p><span style=""color: black;"">1.9.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the resubmission included longer-term follow up data for pre-symptomatic individuals with SMA (two or three <i>SMN2</i> copies) from the NURTURE study. </p><p><span style=""color: black;"">1.9.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that they had previously considered results from the NURTURE study after a median treatment duration of 317.5 days (31 October 2016 data cut). At the current meeting, the Subcommittee considered data from NURTURE after a median treatment duration of 1058 days (29 March 2019 data cut); these results were presented at the 2019 Annual Spinal Muscular Atrophy Researcher Meeting (<a href=""https://n.neurology.org/content/92/15_Supplement/S25.001"" target=""_blank"">Parsons et al. Nusinersen in Infants Who Initiate Treatment in a Presymptomatic Stage of Spinal Muscular Atrophy (SMA): Interim Efficacy and Safety Results From the Phase 2 NURTURE Study. 30</a><a href=""https://n.neurology.org/content/92/15_Supplement/S25.001"" target=""_blank"" style=""font-size: 7pt;"">th </a><a href=""https://n.neurology.org/content/92/15_Supplement/S25.001"" target=""_blank"">June 2019. 23rd Annual Spinal Muscular Atrophy Researcher Meeting, 28 to 30 June 2019, Anaheim, CA</a>).</p><p><span style=""color: black;"">1.9.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted the results of the motor function assessments at the time of the March 2019 data cut of NURTURE, including change in CHOP INTEND scores over time, Hammersmith Infant Neurological Exam (HINE) motor milestone scores over time, and WHO motor milestones. The Subcommittee noted that 80% of children reached the maximum score on the CHOP INTEND scale, 100% (25/25) of children achieved sitting independently, 92% (23/25) walking with assistance, and 88% (22/25) walking alone. </p><p><span style=""color: black;"">1.9.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that at the time of the March 2019 data cut of NURTURE, all patients (n = 25; 100%) were alive and none required permanent ventilation (median time to event could not be estimated). The Subcommittee noted that 4 of 25 patients (all with 2 SMN2 copies) required respiratory support during acute reversible illness.</p><p><span style=""color: black;"">1.9.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that of the patients included in NURTURE, 72% did not meet the protocol definition of clinically manifested SMA at 24 months of age.</p><p><span style=""color: black;"">1.9.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee considered that nusinersen was well tolerated in NURTURE and no new safety signals were identified.</p><p><span style=""color: black;"">1.10.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that the resubmission included longer-term follow up data for childhood-onset SMA (type II or III) from the CHERISH-SHINE study.</p><p><span style=""color: black;"">1.10.1.</span><span style=""color: black; font-size: 7pt;""> </span>The Subcommittee noted that they had previously considered results from the CHERISH-SHINE study after a median treatment duration of 441.5 days (30 June 2017 data cut). At the current meeting, the Subcommittee considered data from CHERISH-SHINE after a median duration of 1175 days (15 October 2018 data cut); these results were presented at the 2019 American Academy of Neurology Annual Meeting (<a href=""https://n.neurology.org/content/92/15_Supplement/P1.6-063"" target=""_blank"">Darras et al. Interim Report on the Safety and Efficacy of Longer term Treatment With Nusinersen in Later onset Spinal Muscular Atrophy (SMA): Results From the SHINE Study. Presented at: 71st American Academy of Neurology (AAN) Meeting. May 4 10, 2019 | Philadelphia, PA. P063</a>).</p><p><span style=""color: black;"">1.10.2.</span><span style=""color: black; font-size: 7pt;""> </span>The Subcommittee noted the results of the motor function assessments at the time of the October 2018 data cut of CHERISH-SHINE, including change in Hammersmith Functional Motor Scale Expanded (HFMSE) scores and Revised Upper Limb Module (RULM) scores. The Subcommittee considered that the results indicated stabilisation in motor function scores in the majority of patients, as opposed to improvement, with the most gains observed in patients who were younger at treatment initiation (&lt;3.69 years at first dose).</p><p><span style=""color: black;"">1.10.3.</span><span style=""color: black; font-size: 7pt;""> </span>The Subcommittee considered that the safety profile of nusinersen in CHERISH-SHINE was consistent with the known profile of nusinersen.</p><p><span style=""color: black;"">1.11.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that the resubmission also included published long-term follow up data for childhood-onset SMA (type II or III) from the CS2-CS12 studies (mean enrolment 965.1 days; <a href=""https://www.ncbi.nlm.nih.gov/pubmed/31019106"" target=""_blank"">Darras et al. Neurology. 2019;92:e2492-e2506</a>).</p><p><span style=""color: black;"">1.11.1.</span><span style=""color: black; font-size: 7pt;""> </span>The Subcommittee noted the results of the motor function assessments for the CS2-CS12 studies, including HFMSE scores, Upper Limb Module (ULM) scores, and the 6-Minute Walk Test. The Subcommittee considered that the results indicated that motor function was maintained or improved over the treatment duration.</p><p><span style=""color: black;"">1.11.2.</span><span style=""color: black; font-size: 7pt;""> </span>The Subcommittee considered that no new safety concerns were identified in these studies, and most adverse events were of mild or moderate severity.</p><p><span style=""color: black;"">1.12.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that the evidence provided by the clinical trials suggests that treatment with nusinersen improves survival, reduces the risk of ventilation, and maintains motor function in patients with pre-symptomatic and infantile-onset SMA and improves motor function in patients with childhood-onset SMA. The Subcommittee also considered that there is a possibility that improved motor function may be associated with a survival advantage in individuals with childhood onset SMA, but that no updated survival data has been provided for this group. </p><p><span style=""color: black;"">1.13.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that the clinical trials investigating nusinersen are of good strength and quality. The Subcommittee noted that despite the follow-up being limited to a duration of less than four years, the updated data indicates that the treatment response is likely to be durable. The Subcommittee also considered that the magnitude of benefit observed in the clinical trials compared with the natural history of the disease gives confidence that nusinersen is likely to provide a clinically meaningful benefit.</p><p><span style=""color: black;"">1.14.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that the NURTURE trial was a single arm Phase 2 trial and therefore the results are associated with some uncertainty due to trial design; however, the Subcommittee considered that even once statistical analysis and peer review has been completed, the effect size reported in the interim analysis is of such a magnitude that it would be unlikely to significantly change the outcomes.</p><p><span style=""color: black;"">1.15.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee was alerted to a publication by Galziou et al. (<a href=""https://www.bmj.com/content/334/7589/349.long"" target=""_blank"">BMJ 2007;334:349-51</a>), in which the authors considered that at times very large treatment effects can overwhelm concerns of bias (the relation between a treatment and its effect being sometimes so dramatic that bias can be ruled out as an explanation). The Subcommittee considered this may be the case with nusinersen, particularly in the treatment of pre-symptomatic individuals with spinal muscular atrophy and two or three <i>SMN2 </i>copies.</p><p><span style=""color: black;"">1.16.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee also noted that the updated data considered at the current meeting, with the exception of <a href=""https://www.ncbi.nlm.nih.gov/pubmed/31019106"" target=""_blank"">Darras et al. Neurology. 2019;92:e2492-e2506</a>, has only been presented at conferences and has not yet been published as peer reviewed scientific articles. </p><p><span style=""color: black;"">1.17.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that the data from the clinical trials suggests that improvements in motor function are more pronounced when treatment is initiated earlier, and that the benefit appears to be greatest in patients treated in the pre-symptomatic stage of SMA. The Subcommittee considered that this is consistent with the pathophysiology of SMA, in which a deficiency in SMN protein leads to irreversible motor neuron degeneration. </p><p><span style=""color: black;"">1.18.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that limiting eligibility for nusinersen to pre‑symptomatic individuals with two or three copies of <i>SMN2</i> would capture those children most likely to develop SMA type Ib, II, and IIIa. The Subcommittee considered that based on the data from the NURTURE trial described above, that these are the individuals with the most potential to benefit and the highest need of a disease-modifying treatment. However, the Subcommittee considered that patients with symptomatic disease also have a high health need with the potential for significant loss in life potential from disability and early death.</p><p><span style=""color: black;"">1.19.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that at the November 2018 meeting, the Subcommittee had considered that patients with SMA type I and those with SMA type II/IIIa were different SMA populations and could be considered separately. However, at the current meeting the Subcommittee considered that in practice, due to SMA being a spectrum disease, that it would be clinically difficult to treat one patient sub-group and not the other. The Subcommittee considered that if nusinersen was to be funded for symptomatic patients with disease onset before three years of age, that the eligibility criteria should include patients with SMA type I, II, and IIIa, as all patients within these groups would significantly benefit from treatment.</p><p><span style=""color: black;"">1.20.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that it is unclear at this stage whether treatment with nusinersen can be stopped once a patient has achieved an optimal response. Members therefore considered that, unless evidence is provided indicating that further deterioration would not occur should treatment be stopped or interrupted, then it is likely that treatment with nusinersen would be lifelong.</p><p><span style=""color: black;"">1.21.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that there may be a small number of pre-symptomatic patients with three copies of <i>SMN2</i> who would go on to develop SMA type IIIb or IV. </p><p><span style=""color: black;"">1.22.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that limiting eligibility for nusinersen to pre-symptomatic patients would require SMA to be included in the newborn screening programme; the validity and implementation of this would need to be investigated if nusinersen was to be funded. One Member also considered that, based on clinical experience, the introduction of newborn screening for a condition frequently results in more than the expected number of patients being identified, and that in the case of SMA this could result in as many as twice as many cases being identified. </p><p><span style=""color: black;"">1.23.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted there are a number of gene therapies under development for the treatment of SMA. The Subcommittee noted that the one-time infusion gene therapy onasemnogene abeparvovec-xioi (Zolgensma) was approved by the U.S. Food &amp; Drug Administration for the treatment of SMA earlier this year.</p><p><span style=""color: black;"">1.24.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that the price proposed by the supplier is still very high, resulting in low cost effectiveness for the application. The Subcommittee considered that if nusinersen was to be funded, it would be important for patients to be included in a registry in order for New Zealand specific data to be collected, helping evidence development internationally.</p><p><span style=""color: black;"">1.25.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that, due to the magnitude of benefit reported in the updated analyses from the NURTURE, ENDEAR-SHINE and CHERISH-SHINE trials, that the data was robust enough to inform a recommendation for pre-symptomatic and symptomatic patients. The Subcommittee considered that there is good quality evidence that treatment with nusinersen improves survival, reduces the risk of ventilation, and maintains motor function in patients with pre-symptomatic and infantile-onset SMA and improves motor function in patients with childhood-onset SMA. The Subcommittee also considered that the greatest benefit is likely to be observed in the pre-symptomatic stage.\xa0</p>', 'fs': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that an application for nusinersen for the treatment of paediatric patients (18 years or under) with spinal muscular atrophy (SMA) types I, II, or IIIa with symptom onset before three years of age was considered by the Rare Disorders Subcommittee in <a href=""https://www.pharmac.govt.nz/assets/ptac-rare-disorders-subcommittee-minutes-2018-11.pdf"" target=""_blank"">November 2018</a>. At this time, the Subcommittee recommended that the application be deferred until longer-term follow-up data were published from the SHINE and/or NURTURE trials. PTAC subsequently reviewed the Record of the November 2018 Rare Disorders Subcommittee in <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2019-02.pdf"" target=""_blank"">February 2019</a>, and agreed with the Subcommittee’s recommendation to defer a decision on nusinersen until longer-term follow-up analyses were available. </p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that a resubmission for nusinersen was received by PHARMAC in August 2019 which included clarification of proposed eligibility criteria for nusinersen, longer-term data from the SHINE and NURTURE trials, and a revised price offer. The Subcommittee also considered correspondence regarding nusinersen received from a Paediatric Neurologist, Muscular Dystrophy New Zealand, and letters of support from the public.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the resubmission requested that the proposed eligibility criteria for nusinersen be widened from the original submission, which was for paediatric patients (18 years or under) with spinal muscular atrophy (SMA) types I, II, or IIIa with symptom onset before three years of age, to include pre-symptomatic individuals who have been genetically diagnosed with SMA.</p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee reviewed the aetiology and pathophysiology of SMA. The Subcommittee noted that SMA represents a continuous spectrum of phenotypes that are categorised into SMA type based on clinical manifestations (ie age of symptom onset and motor milestones achieved). </p><p><span style=""color: black;"">1.4.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted the point raised in the correspondence that individuals with SMA type IIIa do achieve the ability to walk, which differs from the definition described by the Rare Disorders Subcommittee in 2018 (individuals with SMA IIIa are predominantly non-ambulatory). The Subcommittee agreed with the correspondent, noting that individuals with SMA type IIIa do achieve the ability to walk; however, the Subcommittee also noted that these individuals have a high risk of losing this ability and becoming non-ambulatory during youth or adulthood. </p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the phenotypic severity and therefore the type of SMA is, at least in part, modified by the number of copies of the <i>SMN2</i> gene. The Subcommittee considered that, in general, individuals with one copy of <i>SMN2</i> develop SMA type\xa01a (also referred to as type 0, fatal in early infancy), individuals with two copies of <i>SMN2</i> develop SMA type Ib (feeding and respiratory problems, poor or no cephalic control), and individuals with three copies of <i>SMN2</i> can develop SMA of variable disease severity, ranging from type Ic (feeding and respiratory problems, some cephalic control) to SMA type V (ambulatory for normal life-span) (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/31053787"" target=""_blank"">Serra-Juhe &amp; Tizzano. Eur J Hum Genet. 2019; doi: 10.1038/s41431-019-0415-4. [Epub ahead of print]</a>). The Subcommittee noted that individuals with four or five copies of <i>SMN2</i> remain ambulatory and independent well into adulthood and have a normal lifespan. The Subcommittee considered that although it is not a perfect prognostic biomarker, the number of <i>SMN2</i> copies is the best phenotypic modifier of SMA identified to date.</p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that nusinersen is an antisense oligonucleotide therapy that modifies <i>SMN2</i> splicing allowing for translation of full-length SMN protein. The Subcommittee noted that nusinersen does not cure SMA but shifts the severity profile towards a milder disease phenotype.</p><p><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the resubmission included a description of the natural history of individuals with SMA type I and SMA type II and III gathered from published literature. The Subcommittee used these data as a point of comparison when considering the benefit reported for nusinersen in the pivotal trials. </p><p><span style=""color: black;"">1.8.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the resubmission included longer-term follow up data for patients with infantile-onset SMA (most likely to develop SMA type I) from the ENDEAR-SHINE study.</p><p><span style=""color: black;"">1.8.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that they had previously considered results from the ENDEAR-SHINE study after a median treatment duration of 528.6 days (30 June 2017 data cut). At the current meeting, the Subcommittee considered data from ENDEAR-SHINE after a median treatment duration of 987 days (15 October 2018 data cut); these results have not been published in a peer reviewed journal at this time, but were presented at the 2019 American Academy of Neurology Annual Meeting (<a href=""https://n.neurology.org/content/92/15_Supplement/S25.004"" target=""_blank"">Finkel et al. Interim Report on the Safety and Efficacy of Longer term Treatment with Nusinersen in Infantile onset Spinal Muscular Atrophy (SMA): Updated Results From the SHINE Study. Presented at: 2019 American Academy of Neurology Annual Meeting (AAN). May 4 to 10, 2019; Philadelphia, PA.</a>).</p><p><span style=""color: black;"">1.8.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted the results of the motor function assessments at the time of the October 2018 data cut of ENDEAR-SHINE, including change in CHOP INTEND (Children&#39;s Hospital of Philadelphia Infant Test of Neuromuscular Disorders) scores over time and WHO motor milestones. The Subcommittee considered that, in general, the results indicated a reversal of decline and further improvements in motor function over time with nusinersen treatment, and that greater improvements were observed when nusinersen treatment was initiated at a younger age. The Subcommittee noted that no statistical analyses were provided for these data, which limited the interpretation of the results at this stage.</p><p><span style=""color: black;"">1.8.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that 12 of the 24 patients who had received sham control in ENDEAR were alive and without permanent ventilation at baseline in SHINE, and that 7 of 12 of these infants were alive and without permanent ventilation at the time of the October 2018 data cut of ENDEAR-SHINE. The Subcommittee noted the Kaplan-Meier curve for time to death or permanent ventilation presented at the AAN meeting. The Subcommittee noted that the median time to event was 75 weeks in patients previously treated with nusinersen compared with 22.6 weeks for patients who had received the sham control.</p><p><span style=""color: black;"">1.8.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the safety profile was consistent with that previously reported in ENDEAR; the most frequent adverse events were pyrexia and upper respiratory tract infection. </p><p><span style=""color: black;"">1.9.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the resubmission included longer-term follow up data for pre-symptomatic individuals with SMA (two or three <i>SMN2</i> copies) from the NURTURE study. </p><p><span style=""color: black;"">1.9.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that they had previously considered results from the NURTURE study after a median treatment duration of 317.5 days (31 October 2016 data cut). At the current meeting, the Subcommittee considered data from NURTURE after a median treatment duration of 1058 days (29 March 2019 data cut); these results were presented at the 2019 Annual Spinal Muscular Atrophy Researcher Meeting (<a href=""https://n.neurology.org/content/92/15_Supplement/S25.001"" target=""_blank"">Parsons et al. Nusinersen in Infants Who Initiate Treatment in a Presymptomatic Stage of Spinal Muscular Atrophy (SMA): Interim Efficacy and Safety Results From the Phase 2 NURTURE Study. 30</a><a href=""https://n.neurology.org/content/92/15_Supplement/S25.001"" target=""_blank"" style=""font-size: 7pt;"">th </a><a href=""https://n.neurology.org/content/92/15_Supplement/S25.001"" target=""_blank"">June 2019. 23rd Annual Spinal Muscular Atrophy Researcher Meeting, 28 to 30 June 2019, Anaheim, CA</a>).</p><p><span style=""color: black;"">1.9.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted the results of the motor function assessments at the time of the March 2019 data cut of NURTURE, including change in CHOP INTEND scores over time, Hammersmith Infant Neurological Exam (HINE) motor milestone scores over time, and WHO motor milestones. The Subcommittee noted that 80% of children reached the maximum score on the CHOP INTEND scale, 100% (25/25) of children achieved sitting independently, 92% (23/25) walking with assistance, and 88% (22/25) walking alone. </p><p><span style=""color: black;"">1.9.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that at the time of the March 2019 data cut of NURTURE, all patients (n = 25; 100%) were alive and none required permanent ventilation (median time to event could not be estimated). The Subcommittee noted that 4 of 25 patients (all with 2 SMN2 copies) required respiratory support during acute reversible illness.</p><p><span style=""color: black;"">1.9.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that of the patients included in NURTURE, 72% did not meet the protocol definition of clinically manifested SMA at 24 months of age.</p><p><span style=""color: black;"">1.9.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee considered that nusinersen was well tolerated in NURTURE and no new safety signals were identified.</p><p><span style=""color: black;"">1.10.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that the resubmission included longer-term follow up data for childhood-onset SMA (type II or III) from the CHERISH-SHINE study.</p><p><span style=""color: black;"">1.10.1.</span><span style=""color: black; font-size: 7pt;""> </span>The Subcommittee noted that they had previously considered results from the CHERISH-SHINE study after a median treatment duration of 441.5 days (30 June 2017 data cut). At the current meeting, the Subcommittee considered data from CHERISH-SHINE after a median duration of 1175 days (15 October 2018 data cut); these results were presented at the 2019 American Academy of Neurology Annual Meeting (<a href=""https://n.neurology.org/content/92/15_Supplement/P1.6-063"" target=""_blank"">Darras et al. Interim Report on the Safety and Efficacy of Longer term Treatment With Nusinersen in Later onset Spinal Muscular Atrophy (SMA): Results From the SHINE Study. Presented at: 71st American Academy of Neurology (AAN) Meeting. May 4 10, 2019 | Philadelphia, PA. P063</a>).</p><p><span style=""color: black;"">1.10.2.</span><span style=""color: black; font-size: 7pt;""> </span>The Subcommittee noted the results of the motor function assessments at the time of the October 2018 data cut of CHERISH-SHINE, including change in Hammersmith Functional Motor Scale Expanded (HFMSE) scores and Revised Upper Limb Module (RULM) scores. The Subcommittee considered that the results indicated stabilisation in motor function scores in the majority of patients, as opposed to improvement, with the most gains observed in patients who were younger at treatment initiation (&lt;3.69 years at first dose).</p><p><span style=""color: black;"">1.10.3.</span><span style=""color: black; font-size: 7pt;""> </span>The Subcommittee considered that the safety profile of nusinersen in CHERISH-SHINE was consistent with the known profile of nusinersen.</p><p><span style=""color: black;"">1.11.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that the resubmission also included published long-term follow up data for childhood-onset SMA (type II or III) from the CS2-CS12 studies (mean enrolment 965.1 days; <a href=""https://www.ncbi.nlm.nih.gov/pubmed/31019106"" target=""_blank"">Darras et al. Neurology. 2019;92:e2492-e2506</a>).</p><p><span style=""color: black;"">1.11.1.</span><span style=""color: black; font-size: 7pt;""> </span>The Subcommittee noted the results of the motor function assessments for the CS2-CS12 studies, including HFMSE scores, Upper Limb Module (ULM) scores, and the 6-Minute Walk Test. The Subcommittee considered that the results indicated that motor function was maintained or improved over the treatment duration.</p><p><span style=""color: black;"">1.11.2.</span><span style=""color: black; font-size: 7pt;""> </span>The Subcommittee considered that no new safety concerns were identified in these studies, and most adverse events were of mild or moderate severity.</p><p><span style=""color: black;"">1.12.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that the evidence provided by the clinical trials suggests that treatment with nusinersen improves survival, reduces the risk of ventilation, and maintains motor function in patients with pre-symptomatic and infantile-onset SMA and improves motor function in patients with childhood-onset SMA. The Subcommittee also considered that there is a possibility that improved motor function may be associated with a survival advantage in individuals with childhood onset SMA, but that no updated survival data has been provided for this group. </p><p><span style=""color: black;"">1.13.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that the clinical trials investigating nusinersen are of good strength and quality. The Subcommittee noted that despite the follow-up being limited to a duration of less than four years, the updated data indicates that the treatment response is likely to be durable. The Subcommittee also considered that the magnitude of benefit observed in the clinical trials compared with the natural history of the disease gives confidence that nusinersen is likely to provide a clinically meaningful benefit.</p><p><span style=""color: black;"">1.14.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that the NURTURE trial was a single arm Phase 2 trial and therefore the results are associated with some uncertainty due to trial design; however, the Subcommittee considered that even once statistical analysis and peer review has been completed, the effect size reported in the interim analysis is of such a magnitude that it would be unlikely to significantly change the outcomes.</p><p><span style=""color: black;"">1.15.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee was alerted to a publication by Galziou et al. (<a href=""https://www.bmj.com/content/334/7589/349.long"" target=""_blank"">BMJ 2007;334:349-51</a>), in which the authors considered that at times very large treatment effects can overwhelm concerns of bias (the relation between a treatment and its effect being sometimes so dramatic that bias can be ruled out as an explanation). The Subcommittee considered this may be the case with nusinersen, particularly in the treatment of pre-symptomatic individuals with spinal muscular atrophy and two or three <i>SMN2 </i>copies.</p><p><span style=""color: black;"">1.16.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee also noted that the updated data considered at the current meeting, with the exception of <a href=""https://www.ncbi.nlm.nih.gov/pubmed/31019106"" target=""_blank"">Darras et al. Neurology. 2019;92:e2492-e2506</a>, has only been presented at conferences and has not yet been published as peer reviewed scientific articles. </p><p><span style=""color: black;"">1.17.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that the data from the clinical trials suggests that improvements in motor function are more pronounced when treatment is initiated earlier, and that the benefit appears to be greatest in patients treated in the pre-symptomatic stage of SMA. The Subcommittee considered that this is consistent with the pathophysiology of SMA, in which a deficiency in SMN protein leads to irreversible motor neuron degeneration. </p><p><span style=""color: black;"">1.18.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that limiting eligibility for nusinersen to pre‑symptomatic individuals with two or three copies of <i>SMN2</i> would capture those children most likely to develop SMA type Ib, II, and IIIa. The Subcommittee considered that based on the data from the NURTURE trial described above, that these are the individuals with the most potential to benefit and the highest need of a disease-modifying treatment. However, the Subcommittee considered that patients with symptomatic disease also have a high health need with the potential for significant loss in life potential from disability and early death.</p><p><span style=""color: black;"">1.19.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that at the November 2018 meeting, the Subcommittee had considered that patients with SMA type I and those with SMA type II/IIIa were different SMA populations and could be considered separately. However, at the current meeting the Subcommittee considered that in practice, due to SMA being a spectrum disease, that it would be clinically difficult to treat one patient sub-group and not the other. The Subcommittee considered that if nusinersen was to be funded for symptomatic patients with disease onset before three years of age, that the eligibility criteria should include patients with SMA type I, II, and IIIa, as all patients within these groups would significantly benefit from treatment.</p><p><span style=""color: black;"">1.20.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that it is unclear at this stage whether treatment with nusinersen can be stopped once a patient has achieved an optimal response. Members therefore considered that, unless evidence is provided indicating that further deterioration would not occur should treatment be stopped or interrupted, then it is likely that treatment with nusinersen would be lifelong.</p><p><span style=""color: black;"">1.21.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that there may be a small number of pre-symptomatic patients with three copies of <i>SMN2</i> who would go on to develop SMA type IIIb or IV. </p><p><span style=""color: black;"">1.22.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that limiting eligibility for nusinersen to pre-symptomatic patients would require SMA to be included in the newborn screening programme; the validity and implementation of this would need to be investigated if nusinersen was to be funded. One Member also considered that, based on clinical experience, the introduction of newborn screening for a condition frequently results in more than the expected number of patients being identified, and that in the case of SMA this could result in as many as twice as many cases being identified. </p><p><span style=""color: black;"">1.23.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted there are a number of gene therapies under development for the treatment of SMA. The Subcommittee noted that the one-time infusion gene therapy onasemnogene abeparvovec-xioi (Zolgensma) was approved by the U.S. Food &amp; Drug Administration for the treatment of SMA earlier this year.</p><p><span style=""color: black;"">1.24.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that the price proposed by the supplier is still very high, resulting in low cost effectiveness for the application. The Subcommittee considered that if nusinersen was to be funded, it would be important for patients to be included in a registry in order for New Zealand specific data to be collected, helping evidence development internationally.</p><p><span style=""color: black;"">1.25.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that, due to the magnitude of benefit reported in the updated analyses from the NURTURE, ENDEAR-SHINE and CHERISH-SHINE trials, that the data was robust enough to inform a recommendation for pre-symptomatic and symptomatic patients. The Subcommittee considered that there is good quality evidence that treatment with nusinersen improves survival, reduces the risk of ventilation, and maintains motor function in patients with pre-symptomatic and infantile-onset SMA and improves motor function in patients with childhood-onset SMA. The Subcommittee also considered that the greatest benefit is likely to be observed in the pre-symptomatic stage.\xa0</p>', 'change': None}, 'Published_Application': {'s': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee reviewed a resubmission from Biogen Australia Pty Ltd for nusinersen (Spinraza) for the treatment of spinal muscular atrophy that included revised eligibility criteria and updated clinical trial data. </p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'fs': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee reviewed a resubmission from Biogen Australia Pty Ltd for nusinersen (Spinraza) for the treatment of spinal muscular atrophy that included revised eligibility criteria and updated clinical trial data. </p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'change': None}, 'PTAC_Comments': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee also noted the Subcommittee recommendation that nusinersen be funded with a medium priority, within the context of the rare disorders therapeutic area, for the treatment of symptomatic patients with type I, II, and IIIa SMA, subject to Special Authority criteria. PTAC noted the Subcommittee’s recommendation was based on the absence of funded alternatives, the high health need of these individuals and their family/whānau, evidence of survival gain for infantile onset SMA, and meaningful clinical benefit for all symptomatic subgroups considered.\xa0</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee also noted the Subcommittee recommendation that nusinersen be funded with a medium priority, within the context of the rare disorders therapeutic area, for the treatment of symptomatic patients with type I, II, and IIIa SMA, subject to Special Authority criteria. PTAC noted the Subcommittee’s recommendation was based on the absence of funded alternatives, the high health need of these individuals and their family/whānau, evidence of survival gain for infantile onset SMA, and meaningful clinical benefit for all symptomatic subgroups considered.\xa0</p>', 'change': None}, 'Outcome': {'s': 'Medium', 'fs': 'Medium', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2019', 'fs': 'Dec 2019', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Rare Disorders Subcommittee at meeting Tuesday 24 September 2019.', 'fs': 'Clinical advice received from Rare Disorders Subcommittee at meeting Tuesday 24 September 2019.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006tsaDUAQ'}, 'Id': 'a0P2P000006tsaDUAQ', 'Event_Date__c': '2019-12-17', 'Event_Description__c': 'Clinical advice received from Rare Disorders Subcommittee at meeting Tuesday 24 September 2019.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Medium', 'Formatted_Date__c': 'Dec 2019', 'Published_Recommendation__c': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> nusinersen be funded with a <b>high</b> priority, within the context of the rare disorders therapeutic area, for the treatment of pre-symptomatic individuals with spinal muscular atrophy and two or three <i>SMN2 </i>copies, subject to the Special Authority criteria below. This recommendation was<i> </i>based on the absence of funded alternatives, the high health need of these individuals and their family/whānau, longer-term evidence of survival gain and meaningful clinical benefit with nusinersen, and that patients with pre-symptomatic SMA had the greatest potential to benefit.</p><p>\t<b style=""font-size: 9pt;"">Initiation – spinal muscular atrophy (SMA) – pre-symptomatic</b></p><p><span style=""font-size: 9pt;"">Applications only from, or in consultation with, a specialist medical practitioner experienced in the diagnosis and management of SMA associated with a neuromuscular clinic of a recognised hospital in the management of SMA.</span></p><p><span style=""font-size: 9pt;"">Re-assessment required after 12 </span><span style=""font-size: 9pt; color: black;"">months</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Genetic documentation of 5q SMA homozygous gene deletion, homozygous mutation, or compound heterozygous mutation, </span><span style=""font-size: 9pt; color: black;"">identified via newborn screening; </span><span style=""font-size: 9pt;"">and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient must be pre-symptomatic; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient must have only two or three copies of </span><i style=""font-size: 9pt;"">SMN2</i><span style=""font-size: 9pt;"">; and</span></p><p><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment must be given concomitantly with standard of care for this condition; and</span></p><p><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment must not exceed four loading doses (at days 0, 14, 28 and 63); and</span></p><p><span style=""font-size: 9pt;"">6.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient must be 18 years of age or under.</span></p><p><br></p><p><span style=""font-size: 9pt;"">Continuation – spinal muscular atrophy (SMA) – pre-symptomatic</span></p><p><span style=""font-size: 9pt;"">Applications only from, or in consultation with, a specialist medical practitioner experienced in the diagnosis and management of SMA associated with a neuromuscular clinic of a recognised hospital in the management of SMA.</span></p><p><span style=""font-size: 9pt;"">Re-assessment required after 12 months</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient must have had a previous approval for nusinersen; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment must be given concomitantly with standard of care for this condition; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">There has been demonstrated maintenance of motor milestone function (as assessed using age-appropriate scales: the HINE Section 2, CHOP INTEND, or HFMSE) since treatment initiation; and</span></p><p><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The patient does not require invasive permanent assisted ventilation (see Note).</span></p><p><br></p><p><span style=""font-size: 9pt;"">Note: </span></p><p><u style=""font-size: 9pt;"">Invasive permanent assisted ventilation means:</u></p><p><span style=""font-size: 9pt;"">Ventilation via tracheostomy tube for greater than or equal to 16 hours per day.</span></p><p>\xa0</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> nusinersen be funded with a <b>medium</b> priority, within the context of the rare disorders therapeutic area, for the treatment of symptomatic patients with type I, II, and IIIa spinal muscular atrophy, subject to the Special Authority criteria below. This recommendation was based on the absence of funded alternatives, the high health need of these individuals and their family/whānau, evidence of survival gain for infantile onset SMA and meaningful clinical benefit for all symptomatic subgroups considered.</p><p>\t<b style=""font-size: 9pt;"">Initiation – spinal muscular atrophy (SMA) – symptomatic type I, II and IIIa</b></p><p>\t</p><p><span style=""font-size: 9pt;"">Applications only from or in consultation with a specialist medical practitioner experienced in the diagnosis and management of SMA associated with a neuromuscular clinic of a recognised hospital in the management of SMA.</span></p><p><br></p><p><span style=""font-size: 9pt;"">Re-assessment required after 12 months</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Genetic documentation of 5q SMA homozygous gene deletion, homozygous mutation, or compound heterozygous mutation; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient must have experienced the defined signs and symptoms of SMA type I, II or IIIa prior to 3 years of age (see Notes); and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment must be given concomitantly with standard of care for this condition; and</span></p><p><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment must not exceed four loading doses (at days 0, 14, 28 and 63); and</span></p><p><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient must be 18 years of age or under.</span></p><p><br></p><p><span style=""font-size: 9pt;"">Continuation – spinal muscular atrophy (SMA) – symptomatic type I, II and IIIa</span></p><p><span style=""font-size: 9pt;"">Applications only from, or in consultation with a specialist medical practitioner experienced in the diagnosis and management of SMA associated with a neuromuscular clinic of a recognised hospital in the management of SMA.</span></p><p><span style=""font-size: 9pt;"">Re-assessment required after 12 months</span></p><p><br></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient must have had a previous approval for nusinersen; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment must be given concomitantly with standard of care for this condition; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">There has been demonstrated maintenance of motor milestone function (as assessed using age-appropriate scales: the HINE Section 2, CHOP INTEND, or HFMSE) since treatment initiation; and</span></p><p><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment must be ceased when invasive permanent assisted ventilation (see Note) is required in the absence of a potentially reversible cause while being treated with this drug.</span></p><p><br></p><p><span style=""font-size: 9pt;"">Notes: </span></p><p><u style=""font-size: 9pt;"">Invasive permanent assisted ventilation means:</u></p><p><span style=""font-size: 9pt;"">Ventilation via tracheostomy tube for greater than or equal to 16 hours per day.</span></p><p>\xa0</p><p><u style=""font-family: Arial, sans-serif; font-size: 9pt;"">Defined signs and symptoms of type I SMA are:</u></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">i) Onset before 6 months of age; and</span></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">ii) Failure to meet or regression in ability to perform age-appropriate motor milestones.</span></p><p><br></p><p><u style=""font-family: Arial, sans-serif; font-size: 9pt;"">Defined signs and symptoms of type II SMA are:</u></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">i) Onset between 6 and 18 months; and</span></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">ii) Failure to meet or regression in ability to perform age-appropriate motor milestones.</span></p><p><br></p><p><u style=""font-family: Arial, sans-serif; font-size: 9pt;"">Defined signs and symptoms of type IIIa SMA are:</u></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">i) Onset between 18 months and 3 years of age; and</span></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">ii) Failure to meet or regression in ability to perform age-appropriate motor milestones.</span></p>', 'Published_Application__c': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee reviewed a resubmission from Biogen Australia Pty Ltd for nusinersen (Spinraza) for the treatment of spinal muscular atrophy that included revised eligibility criteria and updated clinical trial data. </p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'Published_Discussion__c': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that an application for nusinersen for the treatment of paediatric patients (18 years or under) with spinal muscular atrophy (SMA) types I, II, or IIIa with symptom onset before three years of age was considered by the Rare Disorders Subcommittee in <a href=""https://www.pharmac.govt.nz/assets/ptac-rare-disorders-subcommittee-minutes-2018-11.pdf"" target=""_blank"">November 2018</a>. At this time, the Subcommittee recommended that the application be deferred until longer-term follow-up data were published from the SHINE and/or NURTURE trials. PTAC subsequently reviewed the Record of the November 2018 Rare Disorders Subcommittee in <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2019-02.pdf"" target=""_blank"">February 2019</a>, and agreed with the Subcommittee’s recommendation to defer a decision on nusinersen until longer-term follow-up analyses were available. </p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that a resubmission for nusinersen was received by PHARMAC in August 2019 which included clarification of proposed eligibility criteria for nusinersen, longer-term data from the SHINE and NURTURE trials, and a revised price offer. The Subcommittee also considered correspondence regarding nusinersen received from a Paediatric Neurologist, Muscular Dystrophy New Zealand, and letters of support from the public.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the resubmission requested that the proposed eligibility criteria for nusinersen be widened from the original submission, which was for paediatric patients (18 years or under) with spinal muscular atrophy (SMA) types I, II, or IIIa with symptom onset before three years of age, to include pre-symptomatic individuals who have been genetically diagnosed with SMA.</p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee reviewed the aetiology and pathophysiology of SMA. The Subcommittee noted that SMA represents a continuous spectrum of phenotypes that are categorised into SMA type based on clinical manifestations (ie age of symptom onset and motor milestones achieved). </p><p><span style=""color: black;"">1.4.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted the point raised in the correspondence that individuals with SMA type IIIa do achieve the ability to walk, which differs from the definition described by the Rare Disorders Subcommittee in 2018 (individuals with SMA IIIa are predominantly non-ambulatory). The Subcommittee agreed with the correspondent, noting that individuals with SMA type IIIa do achieve the ability to walk; however, the Subcommittee also noted that these individuals have a high risk of losing this ability and becoming non-ambulatory during youth or adulthood. </p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the phenotypic severity and therefore the type of SMA is, at least in part, modified by the number of copies of the <i>SMN2</i> gene. The Subcommittee considered that, in general, individuals with one copy of <i>SMN2</i> develop SMA type\xa01a (also referred to as type 0, fatal in early infancy), individuals with two copies of <i>SMN2</i> develop SMA type Ib (feeding and respiratory problems, poor or no cephalic control), and individuals with three copies of <i>SMN2</i> can develop SMA of variable disease severity, ranging from type Ic (feeding and respiratory problems, some cephalic control) to SMA type V (ambulatory for normal life-span) (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/31053787"" target=""_blank"">Serra-Juhe &amp; Tizzano. Eur J Hum Genet. 2019; doi: 10.1038/s41431-019-0415-4. [Epub ahead of print]</a>). The Subcommittee noted that individuals with four or five copies of <i>SMN2</i> remain ambulatory and independent well into adulthood and have a normal lifespan. The Subcommittee considered that although it is not a perfect prognostic biomarker, the number of <i>SMN2</i> copies is the best phenotypic modifier of SMA identified to date.</p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that nusinersen is an antisense oligonucleotide therapy that modifies <i>SMN2</i> splicing allowing for translation of full-length SMN protein. The Subcommittee noted that nusinersen does not cure SMA but shifts the severity profile towards a milder disease phenotype.</p><p><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the resubmission included a description of the natural history of individuals with SMA type I and SMA type II and III gathered from published literature. The Subcommittee used these data as a point of comparison when considering the benefit reported for nusinersen in the pivotal trials. </p><p><span style=""color: black;"">1.8.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the resubmission included longer-term follow up data for patients with infantile-onset SMA (most likely to develop SMA type I) from the ENDEAR-SHINE study.</p><p><span style=""color: black;"">1.8.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that they had previously considered results from the ENDEAR-SHINE study after a median treatment duration of 528.6 days (30 June 2017 data cut). At the current meeting, the Subcommittee considered data from ENDEAR-SHINE after a median treatment duration of 987 days (15 October 2018 data cut); these results have not been published in a peer reviewed journal at this time, but were presented at the 2019 American Academy of Neurology Annual Meeting (<a href=""https://n.neurology.org/content/92/15_Supplement/S25.004"" target=""_blank"">Finkel et al. Interim Report on the Safety and Efficacy of Longer term Treatment with Nusinersen in Infantile onset Spinal Muscular Atrophy (SMA): Updated Results From the SHINE Study. Presented at: 2019 American Academy of Neurology Annual Meeting (AAN). May 4 to 10, 2019; Philadelphia, PA.</a>).</p><p><span style=""color: black;"">1.8.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted the results of the motor function assessments at the time of the October 2018 data cut of ENDEAR-SHINE, including change in CHOP INTEND (Children&#39;s Hospital of Philadelphia Infant Test of Neuromuscular Disorders) scores over time and WHO motor milestones. The Subcommittee considered that, in general, the results indicated a reversal of decline and further improvements in motor function over time with nusinersen treatment, and that greater improvements were observed when nusinersen treatment was initiated at a younger age. The Subcommittee noted that no statistical analyses were provided for these data, which limited the interpretation of the results at this stage.</p><p><span style=""color: black;"">1.8.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that 12 of the 24 patients who had received sham control in ENDEAR were alive and without permanent ventilation at baseline in SHINE, and that 7 of 12 of these infants were alive and without permanent ventilation at the time of the October 2018 data cut of ENDEAR-SHINE. The Subcommittee noted the Kaplan-Meier curve for time to death or permanent ventilation presented at the AAN meeting. The Subcommittee noted that the median time to event was 75 weeks in patients previously treated with nusinersen compared with 22.6 weeks for patients who had received the sham control.</p><p><span style=""color: black;"">1.8.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the safety profile was consistent with that previously reported in ENDEAR; the most frequent adverse events were pyrexia and upper respiratory tract infection. </p><p><span style=""color: black;"">1.9.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the resubmission included longer-term follow up data for pre-symptomatic individuals with SMA (two or three <i>SMN2</i> copies) from the NURTURE study. </p><p><span style=""color: black;"">1.9.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that they had previously considered results from the NURTURE study after a median treatment duration of 317.5 days (31 October 2016 data cut). At the current meeting, the Subcommittee considered data from NURTURE after a median treatment duration of 1058 days (29 March 2019 data cut); these results were presented at the 2019 Annual Spinal Muscular Atrophy Researcher Meeting (<a href=""https://n.neurology.org/content/92/15_Supplement/S25.001"" target=""_blank"">Parsons et al. Nusinersen in Infants Who Initiate Treatment in a Presymptomatic Stage of Spinal Muscular Atrophy (SMA): Interim Efficacy and Safety Results From the Phase 2 NURTURE Study. 30</a><a href=""https://n.neurology.org/content/92/15_Supplement/S25.001"" target=""_blank"" style=""font-size: 7pt;"">th </a><a href=""https://n.neurology.org/content/92/15_Supplement/S25.001"" target=""_blank"">June 2019. 23rd Annual Spinal Muscular Atrophy Researcher Meeting, 28 to 30 June 2019, Anaheim, CA</a>).</p><p><span style=""color: black;"">1.9.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted the results of the motor function assessments at the time of the March 2019 data cut of NURTURE, including change in CHOP INTEND scores over time, Hammersmith Infant Neurological Exam (HINE) motor milestone scores over time, and WHO motor milestones. The Subcommittee noted that 80% of children reached the maximum score on the CHOP INTEND scale, 100% (25/25) of children achieved sitting independently, 92% (23/25) walking with assistance, and 88% (22/25) walking alone. </p><p><span style=""color: black;"">1.9.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that at the time of the March 2019 data cut of NURTURE, all patients (n = 25; 100%) were alive and none required permanent ventilation (median time to event could not be estimated). The Subcommittee noted that 4 of 25 patients (all with 2 SMN2 copies) required respiratory support during acute reversible illness.</p><p><span style=""color: black;"">1.9.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that of the patients included in NURTURE, 72% did not meet the protocol definition of clinically manifested SMA at 24 months of age.</p><p><span style=""color: black;"">1.9.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee considered that nusinersen was well tolerated in NURTURE and no new safety signals were identified.</p><p><span style=""color: black;"">1.10.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that the resubmission included longer-term follow up data for childhood-onset SMA (type II or III) from the CHERISH-SHINE study.</p><p><span style=""color: black;"">1.10.1.</span><span style=""color: black; font-size: 7pt;""> </span>The Subcommittee noted that they had previously considered results from the CHERISH-SHINE study after a median treatment duration of 441.5 days (30 June 2017 data cut). At the current meeting, the Subcommittee considered data from CHERISH-SHINE after a median duration of 1175 days (15 October 2018 data cut); these results were presented at the 2019 American Academy of Neurology Annual Meeting (<a href=""https://n.neurology.org/content/92/15_Supplement/P1.6-063"" target=""_blank"">Darras et al. Interim Report on the Safety and Efficacy of Longer term Treatment With Nusinersen in Later onset Spinal Muscular Atrophy (SMA): Results From the SHINE Study. Presented at: 71st American Academy of Neurology (AAN) Meeting. May 4 10, 2019 | Philadelphia, PA. P063</a>).</p><p><span style=""color: black;"">1.10.2.</span><span style=""color: black; font-size: 7pt;""> </span>The Subcommittee noted the results of the motor function assessments at the time of the October 2018 data cut of CHERISH-SHINE, including change in Hammersmith Functional Motor Scale Expanded (HFMSE) scores and Revised Upper Limb Module (RULM) scores. The Subcommittee considered that the results indicated stabilisation in motor function scores in the majority of patients, as opposed to improvement, with the most gains observed in patients who were younger at treatment initiation (&lt;3.69 years at first dose).</p><p><span style=""color: black;"">1.10.3.</span><span style=""color: black; font-size: 7pt;""> </span>The Subcommittee considered that the safety profile of nusinersen in CHERISH-SHINE was consistent with the known profile of nusinersen.</p><p><span style=""color: black;"">1.11.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that the resubmission also included published long-term follow up data for childhood-onset SMA (type II or III) from the CS2-CS12 studies (mean enrolment 965.1 days; <a href=""https://www.ncbi.nlm.nih.gov/pubmed/31019106"" target=""_blank"">Darras et al. Neurology. 2019;92:e2492-e2506</a>).</p><p><span style=""color: black;"">1.11.1.</span><span style=""color: black; font-size: 7pt;""> </span>The Subcommittee noted the results of the motor function assessments for the CS2-CS12 studies, including HFMSE scores, Upper Limb Module (ULM) scores, and the 6-Minute Walk Test. The Subcommittee considered that the results indicated that motor function was maintained or improved over the treatment duration.</p><p><span style=""color: black;"">1.11.2.</span><span style=""color: black; font-size: 7pt;""> </span>The Subcommittee considered that no new safety concerns were identified in these studies, and most adverse events were of mild or moderate severity.</p><p><span style=""color: black;"">1.12.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that the evidence provided by the clinical trials suggests that treatment with nusinersen improves survival, reduces the risk of ventilation, and maintains motor function in patients with pre-symptomatic and infantile-onset SMA and improves motor function in patients with childhood-onset SMA. The Subcommittee also considered that there is a possibility that improved motor function may be associated with a survival advantage in individuals with childhood onset SMA, but that no updated survival data has been provided for this group. </p><p><span style=""color: black;"">1.13.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that the clinical trials investigating nusinersen are of good strength and quality. The Subcommittee noted that despite the follow-up being limited to a duration of less than four years, the updated data indicates that the treatment response is likely to be durable. The Subcommittee also considered that the magnitude of benefit observed in the clinical trials compared with the natural history of the disease gives confidence that nusinersen is likely to provide a clinically meaningful benefit.</p><p><span style=""color: black;"">1.14.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that the NURTURE trial was a single arm Phase 2 trial and therefore the results are associated with some uncertainty due to trial design; however, the Subcommittee considered that even once statistical analysis and peer review has been completed, the effect size reported in the interim analysis is of such a magnitude that it would be unlikely to significantly change the outcomes.</p><p><span style=""color: black;"">1.15.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee was alerted to a publication by Galziou et al. (<a href=""https://www.bmj.com/content/334/7589/349.long"" target=""_blank"">BMJ 2007;334:349-51</a>), in which the authors considered that at times very large treatment effects can overwhelm concerns of bias (the relation between a treatment and its effect being sometimes so dramatic that bias can be ruled out as an explanation). The Subcommittee considered this may be the case with nusinersen, particularly in the treatment of pre-symptomatic individuals with spinal muscular atrophy and two or three <i>SMN2 </i>copies.</p><p><span style=""color: black;"">1.16.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee also noted that the updated data considered at the current meeting, with the exception of <a href=""https://www.ncbi.nlm.nih.gov/pubmed/31019106"" target=""_blank"">Darras et al. Neurology. 2019;92:e2492-e2506</a>, has only been presented at conferences and has not yet been published as peer reviewed scientific articles. </p><p><span style=""color: black;"">1.17.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that the data from the clinical trials suggests that improvements in motor function are more pronounced when treatment is initiated earlier, and that the benefit appears to be greatest in patients treated in the pre-symptomatic stage of SMA. The Subcommittee considered that this is consistent with the pathophysiology of SMA, in which a deficiency in SMN protein leads to irreversible motor neuron degeneration. </p><p><span style=""color: black;"">1.18.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that limiting eligibility for nusinersen to pre‑symptomatic individuals with two or three copies of <i>SMN2</i> would capture those children most likely to develop SMA type Ib, II, and IIIa. The Subcommittee considered that based on the data from the NURTURE trial described above, that these are the individuals with the most potential to benefit and the highest need of a disease-modifying treatment. However, the Subcommittee considered that patients with symptomatic disease also have a high health need with the potential for significant loss in life potential from disability and early death.</p><p><span style=""color: black;"">1.19.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that at the November 2018 meeting, the Subcommittee had considered that patients with SMA type I and those with SMA type II/IIIa were different SMA populations and could be considered separately. However, at the current meeting the Subcommittee considered that in practice, due to SMA being a spectrum disease, that it would be clinically difficult to treat one patient sub-group and not the other. The Subcommittee considered that if nusinersen was to be funded for symptomatic patients with disease onset before three years of age, that the eligibility criteria should include patients with SMA type I, II, and IIIa, as all patients within these groups would significantly benefit from treatment.</p><p><span style=""color: black;"">1.20.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that it is unclear at this stage whether treatment with nusinersen can be stopped once a patient has achieved an optimal response. Members therefore considered that, unless evidence is provided indicating that further deterioration would not occur should treatment be stopped or interrupted, then it is likely that treatment with nusinersen would be lifelong.</p><p><span style=""color: black;"">1.21.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that there may be a small number of pre-symptomatic patients with three copies of <i>SMN2</i> who would go on to develop SMA type IIIb or IV. </p><p><span style=""color: black;"">1.22.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that limiting eligibility for nusinersen to pre-symptomatic patients would require SMA to be included in the newborn screening programme; the validity and implementation of this would need to be investigated if nusinersen was to be funded. One Member also considered that, based on clinical experience, the introduction of newborn screening for a condition frequently results in more than the expected number of patients being identified, and that in the case of SMA this could result in as many as twice as many cases being identified. </p><p><span style=""color: black;"">1.23.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted there are a number of gene therapies under development for the treatment of SMA. The Subcommittee noted that the one-time infusion gene therapy onasemnogene abeparvovec-xioi (Zolgensma) was approved by the U.S. Food &amp; Drug Administration for the treatment of SMA earlier this year.</p><p><span style=""color: black;"">1.24.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that the price proposed by the supplier is still very high, resulting in low cost effectiveness for the application. The Subcommittee considered that if nusinersen was to be funded, it would be important for patients to be included in a registry in order for New Zealand specific data to be collected, helping evidence development internationally.</p><p><span style=""color: black;"">1.25.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that, due to the magnitude of benefit reported in the updated analyses from the NURTURE, ENDEAR-SHINE and CHERISH-SHINE trials, that the data was robust enough to inform a recommendation for pre-symptomatic and symptomatic patients. The Subcommittee considered that there is good quality evidence that treatment with nusinersen improves survival, reduces the risk of ventilation, and maintains motor function in patients with pre-symptomatic and infantile-onset SMA and improves motor function in patients with childhood-onset SMA. The Subcommittee also considered that the greatest benefit is likely to be observed in the pre-symptomatic stage.\xa0</p>', 'PTAC_Comments__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee also noted the Subcommittee recommendation that nusinersen be funded with a medium priority, within the context of the rare disorders therapeutic area, for the treatment of symptomatic patients with type I, II, and IIIa SMA, subject to Special Authority criteria. PTAC noted the Subcommittee’s recommendation was based on the absence of funded alternatives, the high health need of these individuals and their family/whānau, evidence of survival gain for infantile onset SMA, and meaningful clinical benefit for all symptomatic subgroups considered.\xa0</p>', 'Status_History__c': 'a132P000000BFcWQAW'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jan 2020', 'fs': 'Jan 2020', 'change': None}, 'Event_Description': {'s': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Thursday 20 February 2020', 'fs': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Thursday 20 February 2020', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006tsaEUAQ'}, 'Id': 'a0P2P000006tsaEUAQ', 'Event_Date__c': '2020-01-27', 'Event_Description__c': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Thursday 20 February 2020', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Jan 2020', 'Status_History__c': 'a132P000000BQ92QAG'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee <b>recommended </b>that nusinersen be funded with a high priority for the treatment of symptomatic individuals with spinal muscular atrophy type I, II or IIIa prior to 3 years of age, subject to the Special Authority criteria below. This recommendation was based on the absence of funded alternatives, the high health need of these individuals and their family/whanau; and, that although the magnitude of potential health benefit was unlikely to be as large, when compared with the pre-symptomatic population, this group represented the current prevalent population being cared for by the health sector.</p><p>\t<b style=""font-size: 9pt;"">Initiation – spinal muscular atrophy (SMA) – symptomatic type I, II and IIIa</b></p><p>\t</p><p><span style=""font-size: 9pt;"">Applications only from or in consultation with a specialist medical practitioner experienced in the diagnosis and management of SMA associated with a neuromuscular clinic of a recognised hospital in the management of SMA.</span></p><p><br></p><p><span style=""font-size: 9pt;"">Re-assessment required after 12 months</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Genetic documentation of 5q SMA homozygous gene deletion, homozygous mutation, or compound heterozygous mutation; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient must have experienced the defined signs and symptoms of SMA type I, II or IIIa prior to 3 years of age (see Notes); and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment must be given concomitantly with standard of care for this condition; and</span></p><p><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment must not exceed four loading doses (at days 0, 14, 28 and 63); and</span></p><p><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient must be 18 years of age or under.</span></p><p><br></p><p><span style=""font-size: 9pt;"">Continuation – spinal muscular atrophy (SMA) – symptomatic type I, II and IIIa</span></p><p><span style=""font-size: 9pt;"">Applications only from, or in consultation with a specialist medical practitioner experienced in the diagnosis and management of SMA associated with a neuromuscular clinic of a recognised hospital in the management of SMA.</span></p><p><span style=""font-size: 9pt;"">Re-assessment required after 12 months</span></p><p><br></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient must have had a previous approval for nusinersen; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment must be given concomitantly with standard of care for this condition; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">There has been demonstrated maintenance of motor milestone function (as assessed using age-appropriate scales: the HINE Section 2, CHOP INTEND, or HFMSE) since treatment initiation; and</span></p><p><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment must be ceased when non-invasive permanent assisted ventilation (see Note) is required in the absence of a potentially reversible cause while being treated with this drug.</span></p><p><br></p><p><span style=""font-size: 9pt;"">Notes: </span></p><p><u style=""font-size: 9pt;"">Non-invasive permanent assisted ventilation means:</u></p><p><span style=""font-size: 9pt;"">Breathing support administered via nasal cannula or face mask for greater than or equal to 16 hours per day.</span></p><p><br></p><p><u style=""font-family: Arial, sans-serif; font-size: 9pt;"">Defined signs and symptoms of type I SMA are:</u></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">i) Onset before 6 months of age; and</span></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">ii) Failure to meet or regression in ability to perform age-appropriate motor milestones.</span></p><p><br></p><p><u style=""font-family: Arial, sans-serif; font-size: 9pt;"">Defined signs and symptoms of type II SMA are:</u></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">i) Onset between 6 and 18 months; and</span></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">ii) Failure to meet or regression in ability to perform age-appropriate motor milestones.</span></p><p><br></p><p><u style=""font-family: Arial, sans-serif; font-size: 9pt;"">Defined signs and symptoms of type IIIa SMA are:</u></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">i) Onset between 18 months and 3 years of age; and</span></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;""> ii) Failure to meet or regression in ability to perform age-appropriate motor milestones</span></p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee <b>recommended </b>that nusinersen be funded with a high priority for the treatment of symptomatic individuals with spinal muscular atrophy type I, II or IIIa prior to 3 years of age, subject to the Special Authority criteria below. This recommendation was based on the absence of funded alternatives, the high health need of these individuals and their family/whanau; and, that although the magnitude of potential health benefit was unlikely to be as large, when compared with the pre-symptomatic population, this group represented the current prevalent population being cared for by the health sector.</p><p>\t<b style=""font-size: 9pt;"">Initiation – spinal muscular atrophy (SMA) – symptomatic type I, II and IIIa</b></p><p>\t</p><p><span style=""font-size: 9pt;"">Applications only from or in consultation with a specialist medical practitioner experienced in the diagnosis and management of SMA associated with a neuromuscular clinic of a recognised hospital in the management of SMA.</span></p><p><br></p><p><span style=""font-size: 9pt;"">Re-assessment required after 12 months</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Genetic documentation of 5q SMA homozygous gene deletion, homozygous mutation, or compound heterozygous mutation; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient must have experienced the defined signs and symptoms of SMA type I, II or IIIa prior to 3 years of age (see Notes); and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment must be given concomitantly with standard of care for this condition; and</span></p><p><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment must not exceed four loading doses (at days 0, 14, 28 and 63); and</span></p><p><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient must be 18 years of age or under.</span></p><p><br></p><p><span style=""font-size: 9pt;"">Continuation – spinal muscular atrophy (SMA) – symptomatic type I, II and IIIa</span></p><p><span style=""font-size: 9pt;"">Applications only from, or in consultation with a specialist medical practitioner experienced in the diagnosis and management of SMA associated with a neuromuscular clinic of a recognised hospital in the management of SMA.</span></p><p><span style=""font-size: 9pt;"">Re-assessment required after 12 months</span></p><p><br></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient must have had a previous approval for nusinersen; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment must be given concomitantly with standard of care for this condition; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">There has been demonstrated maintenance of motor milestone function (as assessed using age-appropriate scales: the HINE Section 2, CHOP INTEND, or HFMSE) since treatment initiation; and</span></p><p><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment must be ceased when non-invasive permanent assisted ventilation (see Note) is required in the absence of a potentially reversible cause while being treated with this drug.</span></p><p><br></p><p><span style=""font-size: 9pt;"">Notes: </span></p><p><u style=""font-size: 9pt;"">Non-invasive permanent assisted ventilation means:</u></p><p><span style=""font-size: 9pt;"">Breathing support administered via nasal cannula or face mask for greater than or equal to 16 hours per day.</span></p><p><br></p><p><u style=""font-family: Arial, sans-serif; font-size: 9pt;"">Defined signs and symptoms of type I SMA are:</u></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">i) Onset before 6 months of age; and</span></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">ii) Failure to meet or regression in ability to perform age-appropriate motor milestones.</span></p><p><br></p><p><u style=""font-family: Arial, sans-serif; font-size: 9pt;"">Defined signs and symptoms of type II SMA are:</u></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">i) Onset between 6 and 18 months; and</span></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">ii) Failure to meet or regression in ability to perform age-appropriate motor milestones.</span></p><p><br></p><p><u style=""font-family: Arial, sans-serif; font-size: 9pt;"">Defined signs and symptoms of type IIIa SMA are:</u></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">i) Onset between 18 months and 3 years of age; and</span></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;""> ii) Failure to meet or regression in ability to perform age-appropriate motor milestones</span></p>', 'change': None}, 'Published_Discussion': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the Rare Disorders Subcommittee had first reviewed a funding application for nusinersen for symptomatic type I, II and IIIa spinal muscular atrophy (SMA) in November 2018 and that at this time the Subcommittee recommended that the application be deferred until longer-term data were published from the SHINE and/or NURTURE trials.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that it subsequently reviewed the Record of the November 2018 Rare Disorders Subcommittee in February 2019, and agreed with the Subcommittee’s recommendation to defer a decision on nusinersen until longer-term follow up analyses were available. The Committee noted that it had also recommended that consideration of interim analyses of the key trials should be delegated to the Rare Disorders Subcommittee and the Subcommittee could then consider if this data was sufficiently mature to be brought back to the Committee.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that a resubmission from the Supplier, which included longer-term data from the SHINE and NURTURE trials, was considered by the Rare Disorders Subcommittee at its September 2019 meeting. The Committee noted that based on the updated evidence provided in the resubmission the Subcommittee had recommended the following:</p><p>1.3.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>That nusinersen be funded with a high priority, within the context of the rare disorders therapeutic area, for the treatment of pre-symptomatic individuals with SMA and two or three SMN2 copies, subject to Special Authority criteria; and</p><p>1.3.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>That nusinersen be funded with a medium priority, within the context of the rare disorders therapeutic area, for the treatment of symptomatic patients with type I, II and IIIa SMA, subject to Special Authority criteria</p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the Subcommittee’s different funding priorities (high for pre-symptomatic and medium for symptomatic) were largely based on pre-symptomatic patients having longer-term evidence of survival gain and having the greatest potential to benefit [in terms of quality-adjusted life years]. </p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered the original application, the resubmission and all supporting materials that had been submitted, including updated material received since the time of the Rare Disorders Subcommittee.</p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee reprised the pathophysiology of SMA and noted that SMA represents a continuous spectrum of phenotypes that are categorised into SMA type based on clinical manifestations i.e. age of symptom onset and motor milestones achieved.</p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the Supplier was not seeking funding of SMA type 0, and that the funding application was specifically for pre-symptomatic and symptomatic patients with SMA type I, II and IIIa who meet specific eligibility criteria.</p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the phenotypic severity and therefore the type of SMA is, at least in part, modified by the number of copies of the SMN2 gene. The Committee noted that people with 4 or 5 copies of SMN2 generally have a milder clinical trajectory with a normal lifespan; and that those with three or less copy numbers have poorer outcomes.</p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered the epidemiological approach used by the Supplier to estimate the incidence to be appropriate for the NZ setting; however, it considered that patient numbers could be higher if genetic screening for pre-symptomatic SMA was adopted.</p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered the published key evidence (ENDEAR (<a href=""https://www.nejm.org/doi/full/10.1056/NEJMoa1702752"" target=""_blank"">Finkel et al. N Engl J Med. 2017;377:1723‑32</a>) and CHERISH (<a href=""https://www.nejm.org/doi/full/10.1056/NEJMoa1710504"" target=""_blank"">Mercuri et al. N Engl J Med. 2018;378:625-35</a>)) and unpublished evidence provided, including interim results from:</p><p>1.10.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>\xa0<a href=""https://clinicaltrials.gov/ct2/show/NCT02594124?term=SHINE+nusinersen&amp;rank=1"" target=""_blank"">ENDEAR-SHINE</a> presented at the 2019 American Academy of Neurology Annual Meeting (<a href=""https://n.neurology.org/content/92/15_Supplement/S25.004"" target=""_blank"">Finkel et al. Interim Report on the Safety and Efficacy of Longer term Treatment with Nusinersen in Infantile onset Spinal Muscular Atrophy (SMA): Updated Results From the SHINE Study (S25.004). Presented at: 2019 American Academy of Neurology Annual Meeting (AAN). May 4 to 10, 2019; Philadelphia, PA.</a>).</p><p>1.10.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://clinicaltrials.gov/ct2/show/NCT02386553?term=NURTURE"" target=""_blank"">NURTURE</a> presented at the 2019 Annual Spinal Muscular Atrophy Researcher Meeting (<a href=""https://n.neurology.org/content/92/15_Supplement/S25.001"" target=""_blank"">Parsons et al. Nusinersen in Infants Who Initiate Treatment in a Presymptomatic Stage of Spinal Muscular Atrophy (SMA): Interim Efficacy and Safety Results From the Phase 2 NURTURE Study (S25.001). June 30<sup>th</sup> 2019. 23rd Annual Spinal Muscular Atrophy Researcher Meeting, 28 to 30 June 2019, Anaheim, CA</a>).</p><p>1.10.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://clinicaltrials.gov/ct2/show/NCT02594124?term=SHINE+nusinersen&amp;rank=1"" target=""_blank"">CHERISH-SHINE</a> presented at the 2019 American Academy of Neurology Annual Meeting (<a href=""https://n.neurology.org/content/92/15_Supplement/P1.6-063"" target=""_blank"">Darras et al. Interim Report on the Safety and Efficacy of Longer term Treatment With Nusinersen in Later onset Spinal Muscular Atrophy (SMA): Results From the SHINE Study (P1.6-063). Presented at: 71st American Academy of Neurology (AAN) Meeting. May 4 to 10, 2019; Philadelphia, PA.</a>).</p><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Based on the evidence (published and unpublished), the Committee considered that, in summary, patients with pre-symptomatic disease (with either 2 or 3 copies) have the largest magnitude of clinical benefit in terms of life years and quality-adjusted life years gained, but also considered that although the effect size is not as great in the symptomatic population in terms of overall and quality-adjusted survival gains, the improvements seen would still be clinically meaningful. </p><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that although the results [of the trials noted above] are not yet published, and their durations of follow up was limited to date to less than four years, the updated data provided some assurance that the treatment response and large magnitude of effect size was sufficiently persistent and durable to make a recommendation or funding.</p><p>1.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that, based on the evidence reviewed, nusinersen does not cure SMA but likely shifts the severity profile towards a milder disease phenotype. The Committee considered that the evidence supported the assumption that Type I severity is likely to shift to that of a type IIIa severity, but there was uncertainty around whether Type II severity shifts to a IIIa or a IIIb phenotype. Furthermore, the Committee considered that due to the short duration of the data reported to date, it was uncertain that there would be 100% disease re-categorisation of phenotypes to milder phenotypes and considered that assuming so would be an optimistic assumption. The Committee considered that some sensitivity analysis could be modelled to adjust for this area of uncertainty but considered that given the very high price of nusinersen it was unlikely to make a significant improvement to the cost-effectiveness of the treatment.</p><p>1.14.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered the price of treatment was very high resulting in poor cost-effectiveness, and that even if optimistic assumptions around effect size were used, a significant price reduction would need to occur to improve the cost-effectiveness of the application.</p><p>1.15.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the Pharmaceutical Benefits Advisory Committee of Australia (PBAC) had recently (<a href=""http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/pbac-outcomes/2019-11/first-time-decisions-not-to-recommend-11-2019.docx.pdf"" target=""_blank"">Nov 2019</a>) considered funding of nusinersen for the treatment of pre-symptomatic SMA and did not recommend funding for this patient group. In addition, the Committee noted that the PBAC had considered that it may be possible to restrict any future listing of nusinersen for the pre-symptomatic group for patients with <u>&lt;</u>2 copies of SMN2. </p><p>1.16.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered information from the Medical Services Advisory Committee of Australia (MSAC) provided to PBAC on the estimated prognostic value of the number of copies of the SMN2 gene for the severity of SMA (<a href=""http://www.msac.gov.au/internet/msac/publishing.nsf/Content/552F338BE4BEBA0FCA2583D000051738/$File/1589%20-%20Final%20PSD.pdf"" target=""_blank"">MSAC public Summary Document August 2019</a>). The Committee also considered PHARMAC’s estimates, based on the MSAC report,\xa0of the proportion of SMA patients who would be eligible for pre-symptomatic treatment based on the positive predictive and negative predictive values SMN2 copy number threshold of 3 or less copy numbers, and of 2 or less copy numbers.</p><p>1.17.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that in simple terms, PHARMAC’s estimates mean that if pre-symptomatic eligibility was based on 3 or less SMN2 copies, this would result in at least 1 patient every 3 years in New Zealand who would receive lifelong treatment with nusinersen who would otherwise never have met the proposed eligibility criteria for symptomatic SMA. If pre-symptomatic eligibility was based on 2 or less SMN2 copies then this would result in at least 1 patient every 30 years who would otherwise never meet the eligibility criteria for symptomatic SMA. However, the Committee considered that the threshold of 3 or less copy numbers would result in a greater number of true positive results (4.6 patients per year would be treated before the onset of symptoms) than if the threshold was <u>&lt;</u>2 (1.6 individuals per year would be treated before the onset of symptoms); and that based on the available evidence that treatment is most effective if used early in disease, the Committee was supportive of a funding restriction to those with 2 or 3 copy numbers.</p><p>1.18.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that there were two other treatments for SMA on the horizon; onasemnogene abeparvovec (a gene therapy treatment, reported publicly to cost upwards of US$2million per treatment) and risdiplam (an oral treatment). The Committee considered that if either of these agents (or both) were to be funded in future that the comparator of lifelong supportive care until death (at times very early) would change.</p><p>1.19.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered the high health need of both populations (pre-symptomatic and symptomatic SMA type I,II and IIIa), and considered that although there was indicative evidence that the pre-symptomatic population were most likely to benefit from treatment (in terms of overall and quality-adjusted survival gains), that the symptomatic group represent the prevalent pool of patients, currently in the care of the health system, and that this group still has the potential for clinically meaningful improvement. The Committee considered that this could, include health benefit to families/whanau caring for children.</p><p>1.20.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>\xa0The Committee considered that from a practical point of view it would be difficult for clinicians not to be able to offer treatment for patients who are currently in their care, should pre-symptomatic patients i.e. those not born yet, receive access to funded treatment. </p><p>1.21.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that, in theory, treating pre-symptomatic patients could mean that numbers of symptomatic patients decline over time. </p><p>1.22.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered there would be a significant cost to the health system should newborn screening be implemented to identify pre-symptomatic SMA patients. The Committee considered that the additional cost of adding SMA to the Newborn Metabolic Screening Programme (Guthrie testing) needed to be quantified and included in the economic and financial analysis of the funding application.</p><p>1.23.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that supportive care, the treatment comparator, as detailed in the funding application and the clinical trials did not represent the supportive care model of the New Zealand Health system, and that this should be modified in the economic model to be reflective of current practice within the New Zealand Health system.</p><p>1.24.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that currently supportive care for SMA patients in New Zealand requiring respiratory support generally does not include invasive assisted permanent ventilation e.g. intubation, tracheostomy.</p><p>1.25.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that if the New Zealand Health System were to start providing invasive assisted permanent ventilation for patients with SMA, that this would be a significant expense to the health sector and would have a large impact on health system resource.</p><p>1.26.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that, historically, supportive care for patients in NZ with SMA requiring respiratory support has not traditionally included support from a paediatric intensive care unit; however, recently there has been a desire from primary care teams (e.g., neurology or respiratory services) to provide this level of support, partly in an effort to improve current poor\xa0survival times and partly with the hope that a treatment for SMA might be funded in the future. </p><p>1.27.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that SMA patients requiring respiratory support, for intercurrent illnesses, in New Zealand are treated by paediatric intensive care units with non-invasive assisted ventilation support. The Committee considered that, for this reason, the proposed Special Authority criteria should reflect this with regards to measuring ongoing clinical benefit with treatment.</p><p>1.28.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that it should be possible for clinicians to identify if patients are beginning to stop responding to treatment before the proposed Special Authority renewal (stopping) criteria (including requiring non-invasive permanent assisted ventilation support) are reached.</p><p>1.29.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered using the following age-appropriate scales: the Hammersmith Infant Neuromuscular Examination (HINE) Section 2, the Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) or Hammersmith Functional Motor Scale-Expanded (HFMSE) were appropriate scales for assessing motor function as per the proposed Special Authority criteria. </p><p>1.30.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the costs of providing paediatric intensive care support for patients requiring respiratory support needed to be included in the financial and economic analysis for the application; and that the costs derived from a German population, as cited in the application, were likely to be substantially lower than that in the New Zealand Health system. </p><p>1.31.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that, based on the epidemiological information provided, Māori did not appear to be disproportionately affected by SMA compared with the European population; however, the Committee considered that it was difficult to comment on this aspect given small patient numbers. </p><p>1.32.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that, for historical reasons, oncology paediatric patients have a different funding pathway for access to treatments compared with children with other serious illnesses and with adult patients. The Committee noted that nusinersen was not an oncology treatment and therefore considered it appropriate to consider nusinersen alongside all other pharmaceutical funding applications.</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the Rare Disorders Subcommittee had first reviewed a funding application for nusinersen for symptomatic type I, II and IIIa spinal muscular atrophy (SMA) in November 2018 and that at this time the Subcommittee recommended that the application be deferred until longer-term data were published from the SHINE and/or NURTURE trials.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that it subsequently reviewed the Record of the November 2018 Rare Disorders Subcommittee in February 2019, and agreed with the Subcommittee’s recommendation to defer a decision on nusinersen until longer-term follow up analyses were available. The Committee noted that it had also recommended that consideration of interim analyses of the key trials should be delegated to the Rare Disorders Subcommittee and the Subcommittee could then consider if this data was sufficiently mature to be brought back to the Committee.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that a resubmission from the Supplier, which included longer-term data from the SHINE and NURTURE trials, was considered by the Rare Disorders Subcommittee at its September 2019 meeting. The Committee noted that based on the updated evidence provided in the resubmission the Subcommittee had recommended the following:</p><p>1.3.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>That nusinersen be funded with a high priority, within the context of the rare disorders therapeutic area, for the treatment of pre-symptomatic individuals with SMA and two or three SMN2 copies, subject to Special Authority criteria; and</p><p>1.3.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>That nusinersen be funded with a medium priority, within the context of the rare disorders therapeutic area, for the treatment of symptomatic patients with type I, II and IIIa SMA, subject to Special Authority criteria</p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the Subcommittee’s different funding priorities (high for pre-symptomatic and medium for symptomatic) were largely based on pre-symptomatic patients having longer-term evidence of survival gain and having the greatest potential to benefit [in terms of quality-adjusted life years]. </p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered the original application, the resubmission and all supporting materials that had been submitted, including updated material received since the time of the Rare Disorders Subcommittee.</p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee reprised the pathophysiology of SMA and noted that SMA represents a continuous spectrum of phenotypes that are categorised into SMA type based on clinical manifestations i.e. age of symptom onset and motor milestones achieved.</p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the Supplier was not seeking funding of SMA type 0, and that the funding application was specifically for pre-symptomatic and symptomatic patients with SMA type I, II and IIIa who meet specific eligibility criteria.</p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the phenotypic severity and therefore the type of SMA is, at least in part, modified by the number of copies of the SMN2 gene. The Committee noted that people with 4 or 5 copies of SMN2 generally have a milder clinical trajectory with a normal lifespan; and that those with three or less copy numbers have poorer outcomes.</p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered the epidemiological approach used by the Supplier to estimate the incidence to be appropriate for the NZ setting; however, it considered that patient numbers could be higher if genetic screening for pre-symptomatic SMA was adopted.</p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered the published key evidence (ENDEAR (<a href=""https://www.nejm.org/doi/full/10.1056/NEJMoa1702752"" target=""_blank"">Finkel et al. N Engl J Med. 2017;377:1723‑32</a>) and CHERISH (<a href=""https://www.nejm.org/doi/full/10.1056/NEJMoa1710504"" target=""_blank"">Mercuri et al. N Engl J Med. 2018;378:625-35</a>)) and unpublished evidence provided, including interim results from:</p><p>1.10.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>\xa0<a href=""https://clinicaltrials.gov/ct2/show/NCT02594124?term=SHINE+nusinersen&amp;rank=1"" target=""_blank"">ENDEAR-SHINE</a> presented at the 2019 American Academy of Neurology Annual Meeting (<a href=""https://n.neurology.org/content/92/15_Supplement/S25.004"" target=""_blank"">Finkel et al. Interim Report on the Safety and Efficacy of Longer term Treatment with Nusinersen in Infantile onset Spinal Muscular Atrophy (SMA): Updated Results From the SHINE Study (S25.004). Presented at: 2019 American Academy of Neurology Annual Meeting (AAN). May 4 to 10, 2019; Philadelphia, PA.</a>).</p><p>1.10.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://clinicaltrials.gov/ct2/show/NCT02386553?term=NURTURE"" target=""_blank"">NURTURE</a> presented at the 2019 Annual Spinal Muscular Atrophy Researcher Meeting (<a href=""https://n.neurology.org/content/92/15_Supplement/S25.001"" target=""_blank"">Parsons et al. Nusinersen in Infants Who Initiate Treatment in a Presymptomatic Stage of Spinal Muscular Atrophy (SMA): Interim Efficacy and Safety Results From the Phase 2 NURTURE Study (S25.001). June 30<sup>th</sup> 2019. 23rd Annual Spinal Muscular Atrophy Researcher Meeting, 28 to 30 June 2019, Anaheim, CA</a>).</p><p>1.10.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://clinicaltrials.gov/ct2/show/NCT02594124?term=SHINE+nusinersen&amp;rank=1"" target=""_blank"">CHERISH-SHINE</a> presented at the 2019 American Academy of Neurology Annual Meeting (<a href=""https://n.neurology.org/content/92/15_Supplement/P1.6-063"" target=""_blank"">Darras et al. Interim Report on the Safety and Efficacy of Longer term Treatment With Nusinersen in Later onset Spinal Muscular Atrophy (SMA): Results From the SHINE Study (P1.6-063). Presented at: 71st American Academy of Neurology (AAN) Meeting. May 4 to 10, 2019; Philadelphia, PA.</a>).</p><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Based on the evidence (published and unpublished), the Committee considered that, in summary, patients with pre-symptomatic disease (with either 2 or 3 copies) have the largest magnitude of clinical benefit in terms of life years and quality-adjusted life years gained, but also considered that although the effect size is not as great in the symptomatic population in terms of overall and quality-adjusted survival gains, the improvements seen would still be clinically meaningful. </p><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that although the results [of the trials noted above] are not yet published, and their durations of follow up was limited to date to less than four years, the updated data provided some assurance that the treatment response and large magnitude of effect size was sufficiently persistent and durable to make a recommendation or funding.</p><p>1.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that, based on the evidence reviewed, nusinersen does not cure SMA but likely shifts the severity profile towards a milder disease phenotype. The Committee considered that the evidence supported the assumption that Type I severity is likely to shift to that of a type IIIa severity, but there was uncertainty around whether Type II severity shifts to a IIIa or a IIIb phenotype. Furthermore, the Committee considered that due to the short duration of the data reported to date, it was uncertain that there would be 100% disease re-categorisation of phenotypes to milder phenotypes and considered that assuming so would be an optimistic assumption. The Committee considered that some sensitivity analysis could be modelled to adjust for this area of uncertainty but considered that given the very high price of nusinersen it was unlikely to make a significant improvement to the cost-effectiveness of the treatment.</p><p>1.14.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered the price of treatment was very high resulting in poor cost-effectiveness, and that even if optimistic assumptions around effect size were used, a significant price reduction would need to occur to improve the cost-effectiveness of the application.</p><p>1.15.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the Pharmaceutical Benefits Advisory Committee of Australia (PBAC) had recently (<a href=""http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/pbac-outcomes/2019-11/first-time-decisions-not-to-recommend-11-2019.docx.pdf"" target=""_blank"">Nov 2019</a>) considered funding of nusinersen for the treatment of pre-symptomatic SMA and did not recommend funding for this patient group. In addition, the Committee noted that the PBAC had considered that it may be possible to restrict any future listing of nusinersen for the pre-symptomatic group for patients with <u>&lt;</u>2 copies of SMN2. </p><p>1.16.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered information from the Medical Services Advisory Committee of Australia (MSAC) provided to PBAC on the estimated prognostic value of the number of copies of the SMN2 gene for the severity of SMA (<a href=""http://www.msac.gov.au/internet/msac/publishing.nsf/Content/552F338BE4BEBA0FCA2583D000051738/$File/1589%20-%20Final%20PSD.pdf"" target=""_blank"">MSAC public Summary Document August 2019</a>). The Committee also considered PHARMAC’s estimates, based on the MSAC report,\xa0of the proportion of SMA patients who would be eligible for pre-symptomatic treatment based on the positive predictive and negative predictive values SMN2 copy number threshold of 3 or less copy numbers, and of 2 or less copy numbers.</p><p>1.17.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that in simple terms, PHARMAC’s estimates mean that if pre-symptomatic eligibility was based on 3 or less SMN2 copies, this would result in at least 1 patient every 3 years in New Zealand who would receive lifelong treatment with nusinersen who would otherwise never have met the proposed eligibility criteria for symptomatic SMA. If pre-symptomatic eligibility was based on 2 or less SMN2 copies then this would result in at least 1 patient every 30 years who would otherwise never meet the eligibility criteria for symptomatic SMA. However, the Committee considered that the threshold of 3 or less copy numbers would result in a greater number of true positive results (4.6 patients per year would be treated before the onset of symptoms) than if the threshold was <u>&lt;</u>2 (1.6 individuals per year would be treated before the onset of symptoms); and that based on the available evidence that treatment is most effective if used early in disease, the Committee was supportive of a funding restriction to those with 2 or 3 copy numbers.</p><p>1.18.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that there were two other treatments for SMA on the horizon; onasemnogene abeparvovec (a gene therapy treatment, reported publicly to cost upwards of US$2million per treatment) and risdiplam (an oral treatment). The Committee considered that if either of these agents (or both) were to be funded in future that the comparator of lifelong supportive care until death (at times very early) would change.</p><p>1.19.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered the high health need of both populations (pre-symptomatic and symptomatic SMA type I,II and IIIa), and considered that although there was indicative evidence that the pre-symptomatic population were most likely to benefit from treatment (in terms of overall and quality-adjusted survival gains), that the symptomatic group represent the prevalent pool of patients, currently in the care of the health system, and that this group still has the potential for clinically meaningful improvement. The Committee considered that this could, include health benefit to families/whanau caring for children.</p><p>1.20.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>\xa0The Committee considered that from a practical point of view it would be difficult for clinicians not to be able to offer treatment for patients who are currently in their care, should pre-symptomatic patients i.e. those not born yet, receive access to funded treatment. </p><p>1.21.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that, in theory, treating pre-symptomatic patients could mean that numbers of symptomatic patients decline over time. </p><p>1.22.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered there would be a significant cost to the health system should newborn screening be implemented to identify pre-symptomatic SMA patients. The Committee considered that the additional cost of adding SMA to the Newborn Metabolic Screening Programme (Guthrie testing) needed to be quantified and included in the economic and financial analysis of the funding application.</p><p>1.23.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that supportive care, the treatment comparator, as detailed in the funding application and the clinical trials did not represent the supportive care model of the New Zealand Health system, and that this should be modified in the economic model to be reflective of current practice within the New Zealand Health system.</p><p>1.24.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that currently supportive care for SMA patients in New Zealand requiring respiratory support generally does not include invasive assisted permanent ventilation e.g. intubation, tracheostomy.</p><p>1.25.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that if the New Zealand Health System were to start providing invasive assisted permanent ventilation for patients with SMA, that this would be a significant expense to the health sector and would have a large impact on health system resource.</p><p>1.26.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that, historically, supportive care for patients in NZ with SMA requiring respiratory support has not traditionally included support from a paediatric intensive care unit; however, recently there has been a desire from primary care teams (e.g., neurology or respiratory services) to provide this level of support, partly in an effort to improve current poor\xa0survival times and partly with the hope that a treatment for SMA might be funded in the future. </p><p>1.27.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that SMA patients requiring respiratory support, for intercurrent illnesses, in New Zealand are treated by paediatric intensive care units with non-invasive assisted ventilation support. The Committee considered that, for this reason, the proposed Special Authority criteria should reflect this with regards to measuring ongoing clinical benefit with treatment.</p><p>1.28.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that it should be possible for clinicians to identify if patients are beginning to stop responding to treatment before the proposed Special Authority renewal (stopping) criteria (including requiring non-invasive permanent assisted ventilation support) are reached.</p><p>1.29.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered using the following age-appropriate scales: the Hammersmith Infant Neuromuscular Examination (HINE) Section 2, the Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) or Hammersmith Functional Motor Scale-Expanded (HFMSE) were appropriate scales for assessing motor function as per the proposed Special Authority criteria. </p><p>1.30.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the costs of providing paediatric intensive care support for patients requiring respiratory support needed to be included in the financial and economic analysis for the application; and that the costs derived from a German population, as cited in the application, were likely to be substantially lower than that in the New Zealand Health system. </p><p>1.31.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that, based on the epidemiological information provided, Māori did not appear to be disproportionately affected by SMA compared with the European population; however, the Committee considered that it was difficult to comment on this aspect given small patient numbers. </p><p>1.32.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that, for historical reasons, oncology paediatric patients have a different funding pathway for access to treatments compared with children with other serious illnesses and with adult patients. The Committee noted that nusinersen was not an oncology treatment and therefore considered it appropriate to consider nusinersen alongside all other pharmaceutical funding applications.</p>', 'change': None}, 'Published_Application': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee reviewed the application for nusinersen in the treatment of spinal muscular atrophy</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee reviewed the application for nusinersen in the treatment of spinal muscular atrophy</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'High', 'fs': 'High', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2020', 'fs': 'May 2020', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 20 February 2020.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 20 February 2020.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006tsaHUAQ'}, 'Id': 'a0P2P000006tsaHUAQ', 'Event_Date__c': '2020-05-15', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 20 February 2020.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'High', 'Formatted_Date__c': 'May 2020', 'Published_Recommendation__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee <b>recommended </b>that nusinersen be funded with a high priority for the treatment of symptomatic individuals with spinal muscular atrophy type I, II or IIIa prior to 3 years of age, subject to the Special Authority criteria below. This recommendation was based on the absence of funded alternatives, the high health need of these individuals and their family/whanau; and, that although the magnitude of potential health benefit was unlikely to be as large, when compared with the pre-symptomatic population, this group represented the current prevalent population being cared for by the health sector.</p><p>\t<b style=""font-size: 9pt;"">Initiation – spinal muscular atrophy (SMA) – symptomatic type I, II and IIIa</b></p><p>\t</p><p><span style=""font-size: 9pt;"">Applications only from or in consultation with a specialist medical practitioner experienced in the diagnosis and management of SMA associated with a neuromuscular clinic of a recognised hospital in the management of SMA.</span></p><p><br></p><p><span style=""font-size: 9pt;"">Re-assessment required after 12 months</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Genetic documentation of 5q SMA homozygous gene deletion, homozygous mutation, or compound heterozygous mutation; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient must have experienced the defined signs and symptoms of SMA type I, II or IIIa prior to 3 years of age (see Notes); and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment must be given concomitantly with standard of care for this condition; and</span></p><p><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment must not exceed four loading doses (at days 0, 14, 28 and 63); and</span></p><p><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient must be 18 years of age or under.</span></p><p><br></p><p><span style=""font-size: 9pt;"">Continuation – spinal muscular atrophy (SMA) – symptomatic type I, II and IIIa</span></p><p><span style=""font-size: 9pt;"">Applications only from, or in consultation with a specialist medical practitioner experienced in the diagnosis and management of SMA associated with a neuromuscular clinic of a recognised hospital in the management of SMA.</span></p><p><span style=""font-size: 9pt;"">Re-assessment required after 12 months</span></p><p><br></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient must have had a previous approval for nusinersen; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment must be given concomitantly with standard of care for this condition; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">There has been demonstrated maintenance of motor milestone function (as assessed using age-appropriate scales: the HINE Section 2, CHOP INTEND, or HFMSE) since treatment initiation; and</span></p><p><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment must be ceased when non-invasive permanent assisted ventilation (see Note) is required in the absence of a potentially reversible cause while being treated with this drug.</span></p><p><br></p><p><span style=""font-size: 9pt;"">Notes: </span></p><p><u style=""font-size: 9pt;"">Non-invasive permanent assisted ventilation means:</u></p><p><span style=""font-size: 9pt;"">Breathing support administered via nasal cannula or face mask for greater than or equal to 16 hours per day.</span></p><p><br></p><p><u style=""font-family: Arial, sans-serif; font-size: 9pt;"">Defined signs and symptoms of type I SMA are:</u></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">i) Onset before 6 months of age; and</span></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">ii) Failure to meet or regression in ability to perform age-appropriate motor milestones.</span></p><p><br></p><p><u style=""font-family: Arial, sans-serif; font-size: 9pt;"">Defined signs and symptoms of type II SMA are:</u></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">i) Onset between 6 and 18 months; and</span></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">ii) Failure to meet or regression in ability to perform age-appropriate motor milestones.</span></p><p><br></p><p><u style=""font-family: Arial, sans-serif; font-size: 9pt;"">Defined signs and symptoms of type IIIa SMA are:</u></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">i) Onset between 18 months and 3 years of age; and</span></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;""> ii) Failure to meet or regression in ability to perform age-appropriate motor milestones</span></p>', 'Published_Application__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee reviewed the application for nusinersen in the treatment of spinal muscular atrophy</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'Published_Discussion__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the Rare Disorders Subcommittee had first reviewed a funding application for nusinersen for symptomatic type I, II and IIIa spinal muscular atrophy (SMA) in November 2018 and that at this time the Subcommittee recommended that the application be deferred until longer-term data were published from the SHINE and/or NURTURE trials.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that it subsequently reviewed the Record of the November 2018 Rare Disorders Subcommittee in February 2019, and agreed with the Subcommittee’s recommendation to defer a decision on nusinersen until longer-term follow up analyses were available. The Committee noted that it had also recommended that consideration of interim analyses of the key trials should be delegated to the Rare Disorders Subcommittee and the Subcommittee could then consider if this data was sufficiently mature to be brought back to the Committee.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that a resubmission from the Supplier, which included longer-term data from the SHINE and NURTURE trials, was considered by the Rare Disorders Subcommittee at its September 2019 meeting. The Committee noted that based on the updated evidence provided in the resubmission the Subcommittee had recommended the following:</p><p>1.3.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>That nusinersen be funded with a high priority, within the context of the rare disorders therapeutic area, for the treatment of pre-symptomatic individuals with SMA and two or three SMN2 copies, subject to Special Authority criteria; and</p><p>1.3.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>That nusinersen be funded with a medium priority, within the context of the rare disorders therapeutic area, for the treatment of symptomatic patients with type I, II and IIIa SMA, subject to Special Authority criteria</p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the Subcommittee’s different funding priorities (high for pre-symptomatic and medium for symptomatic) were largely based on pre-symptomatic patients having longer-term evidence of survival gain and having the greatest potential to benefit [in terms of quality-adjusted life years]. </p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered the original application, the resubmission and all supporting materials that had been submitted, including updated material received since the time of the Rare Disorders Subcommittee.</p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee reprised the pathophysiology of SMA and noted that SMA represents a continuous spectrum of phenotypes that are categorised into SMA type based on clinical manifestations i.e. age of symptom onset and motor milestones achieved.</p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the Supplier was not seeking funding of SMA type 0, and that the funding application was specifically for pre-symptomatic and symptomatic patients with SMA type I, II and IIIa who meet specific eligibility criteria.</p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the phenotypic severity and therefore the type of SMA is, at least in part, modified by the number of copies of the SMN2 gene. The Committee noted that people with 4 or 5 copies of SMN2 generally have a milder clinical trajectory with a normal lifespan; and that those with three or less copy numbers have poorer outcomes.</p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered the epidemiological approach used by the Supplier to estimate the incidence to be appropriate for the NZ setting; however, it considered that patient numbers could be higher if genetic screening for pre-symptomatic SMA was adopted.</p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered the published key evidence (ENDEAR (<a href=""https://www.nejm.org/doi/full/10.1056/NEJMoa1702752"" target=""_blank"">Finkel et al. N Engl J Med. 2017;377:1723‑32</a>) and CHERISH (<a href=""https://www.nejm.org/doi/full/10.1056/NEJMoa1710504"" target=""_blank"">Mercuri et al. N Engl J Med. 2018;378:625-35</a>)) and unpublished evidence provided, including interim results from:</p><p>1.10.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>\xa0<a href=""https://clinicaltrials.gov/ct2/show/NCT02594124?term=SHINE+nusinersen&amp;rank=1"" target=""_blank"">ENDEAR-SHINE</a> presented at the 2019 American Academy of Neurology Annual Meeting (<a href=""https://n.neurology.org/content/92/15_Supplement/S25.004"" target=""_blank"">Finkel et al. Interim Report on the Safety and Efficacy of Longer term Treatment with Nusinersen in Infantile onset Spinal Muscular Atrophy (SMA): Updated Results From the SHINE Study (S25.004). Presented at: 2019 American Academy of Neurology Annual Meeting (AAN). May 4 to 10, 2019; Philadelphia, PA.</a>).</p><p>1.10.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://clinicaltrials.gov/ct2/show/NCT02386553?term=NURTURE"" target=""_blank"">NURTURE</a> presented at the 2019 Annual Spinal Muscular Atrophy Researcher Meeting (<a href=""https://n.neurology.org/content/92/15_Supplement/S25.001"" target=""_blank"">Parsons et al. Nusinersen in Infants Who Initiate Treatment in a Presymptomatic Stage of Spinal Muscular Atrophy (SMA): Interim Efficacy and Safety Results From the Phase 2 NURTURE Study (S25.001). June 30<sup>th</sup> 2019. 23rd Annual Spinal Muscular Atrophy Researcher Meeting, 28 to 30 June 2019, Anaheim, CA</a>).</p><p>1.10.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://clinicaltrials.gov/ct2/show/NCT02594124?term=SHINE+nusinersen&amp;rank=1"" target=""_blank"">CHERISH-SHINE</a> presented at the 2019 American Academy of Neurology Annual Meeting (<a href=""https://n.neurology.org/content/92/15_Supplement/P1.6-063"" target=""_blank"">Darras et al. Interim Report on the Safety and Efficacy of Longer term Treatment With Nusinersen in Later onset Spinal Muscular Atrophy (SMA): Results From the SHINE Study (P1.6-063). Presented at: 71st American Academy of Neurology (AAN) Meeting. May 4 to 10, 2019; Philadelphia, PA.</a>).</p><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Based on the evidence (published and unpublished), the Committee considered that, in summary, patients with pre-symptomatic disease (with either 2 or 3 copies) have the largest magnitude of clinical benefit in terms of life years and quality-adjusted life years gained, but also considered that although the effect size is not as great in the symptomatic population in terms of overall and quality-adjusted survival gains, the improvements seen would still be clinically meaningful. </p><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that although the results [of the trials noted above] are not yet published, and their durations of follow up was limited to date to less than four years, the updated data provided some assurance that the treatment response and large magnitude of effect size was sufficiently persistent and durable to make a recommendation or funding.</p><p>1.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that, based on the evidence reviewed, nusinersen does not cure SMA but likely shifts the severity profile towards a milder disease phenotype. The Committee considered that the evidence supported the assumption that Type I severity is likely to shift to that of a type IIIa severity, but there was uncertainty around whether Type II severity shifts to a IIIa or a IIIb phenotype. Furthermore, the Committee considered that due to the short duration of the data reported to date, it was uncertain that there would be 100% disease re-categorisation of phenotypes to milder phenotypes and considered that assuming so would be an optimistic assumption. The Committee considered that some sensitivity analysis could be modelled to adjust for this area of uncertainty but considered that given the very high price of nusinersen it was unlikely to make a significant improvement to the cost-effectiveness of the treatment.</p><p>1.14.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered the price of treatment was very high resulting in poor cost-effectiveness, and that even if optimistic assumptions around effect size were used, a significant price reduction would need to occur to improve the cost-effectiveness of the application.</p><p>1.15.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the Pharmaceutical Benefits Advisory Committee of Australia (PBAC) had recently (<a href=""http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/pbac-outcomes/2019-11/first-time-decisions-not-to-recommend-11-2019.docx.pdf"" target=""_blank"">Nov 2019</a>) considered funding of nusinersen for the treatment of pre-symptomatic SMA and did not recommend funding for this patient group. In addition, the Committee noted that the PBAC had considered that it may be possible to restrict any future listing of nusinersen for the pre-symptomatic group for patients with <u>&lt;</u>2 copies of SMN2. </p><p>1.16.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered information from the Medical Services Advisory Committee of Australia (MSAC) provided to PBAC on the estimated prognostic value of the number of copies of the SMN2 gene for the severity of SMA (<a href=""http://www.msac.gov.au/internet/msac/publishing.nsf/Content/552F338BE4BEBA0FCA2583D000051738/$File/1589%20-%20Final%20PSD.pdf"" target=""_blank"">MSAC public Summary Document August 2019</a>). The Committee also considered PHARMAC’s estimates, based on the MSAC report,\xa0of the proportion of SMA patients who would be eligible for pre-symptomatic treatment based on the positive predictive and negative predictive values SMN2 copy number threshold of 3 or less copy numbers, and of 2 or less copy numbers.</p><p>1.17.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that in simple terms, PHARMAC’s estimates mean that if pre-symptomatic eligibility was based on 3 or less SMN2 copies, this would result in at least 1 patient every 3 years in New Zealand who would receive lifelong treatment with nusinersen who would otherwise never have met the proposed eligibility criteria for symptomatic SMA. If pre-symptomatic eligibility was based on 2 or less SMN2 copies then this would result in at least 1 patient every 30 years who would otherwise never meet the eligibility criteria for symptomatic SMA. However, the Committee considered that the threshold of 3 or less copy numbers would result in a greater number of true positive results (4.6 patients per year would be treated before the onset of symptoms) than if the threshold was <u>&lt;</u>2 (1.6 individuals per year would be treated before the onset of symptoms); and that based on the available evidence that treatment is most effective if used early in disease, the Committee was supportive of a funding restriction to those with 2 or 3 copy numbers.</p><p>1.18.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that there were two other treatments for SMA on the horizon; onasemnogene abeparvovec (a gene therapy treatment, reported publicly to cost upwards of US$2million per treatment) and risdiplam (an oral treatment). The Committee considered that if either of these agents (or both) were to be funded in future that the comparator of lifelong supportive care until death (at times very early) would change.</p><p>1.19.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered the high health need of both populations (pre-symptomatic and symptomatic SMA type I,II and IIIa), and considered that although there was indicative evidence that the pre-symptomatic population were most likely to benefit from treatment (in terms of overall and quality-adjusted survival gains), that the symptomatic group represent the prevalent pool of patients, currently in the care of the health system, and that this group still has the potential for clinically meaningful improvement. The Committee considered that this could, include health benefit to families/whanau caring for children.</p><p>1.20.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>\xa0The Committee considered that from a practical point of view it would be difficult for clinicians not to be able to offer treatment for patients who are currently in their care, should pre-symptomatic patients i.e. those not born yet, receive access to funded treatment. </p><p>1.21.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that, in theory, treating pre-symptomatic patients could mean that numbers of symptomatic patients decline over time. </p><p>1.22.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered there would be a significant cost to the health system should newborn screening be implemented to identify pre-symptomatic SMA patients. The Committee considered that the additional cost of adding SMA to the Newborn Metabolic Screening Programme (Guthrie testing) needed to be quantified and included in the economic and financial analysis of the funding application.</p><p>1.23.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that supportive care, the treatment comparator, as detailed in the funding application and the clinical trials did not represent the supportive care model of the New Zealand Health system, and that this should be modified in the economic model to be reflective of current practice within the New Zealand Health system.</p><p>1.24.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that currently supportive care for SMA patients in New Zealand requiring respiratory support generally does not include invasive assisted permanent ventilation e.g. intubation, tracheostomy.</p><p>1.25.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that if the New Zealand Health System were to start providing invasive assisted permanent ventilation for patients with SMA, that this would be a significant expense to the health sector and would have a large impact on health system resource.</p><p>1.26.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that, historically, supportive care for patients in NZ with SMA requiring respiratory support has not traditionally included support from a paediatric intensive care unit; however, recently there has been a desire from primary care teams (e.g., neurology or respiratory services) to provide this level of support, partly in an effort to improve current poor\xa0survival times and partly with the hope that a treatment for SMA might be funded in the future. </p><p>1.27.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that SMA patients requiring respiratory support, for intercurrent illnesses, in New Zealand are treated by paediatric intensive care units with non-invasive assisted ventilation support. The Committee considered that, for this reason, the proposed Special Authority criteria should reflect this with regards to measuring ongoing clinical benefit with treatment.</p><p>1.28.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that it should be possible for clinicians to identify if patients are beginning to stop responding to treatment before the proposed Special Authority renewal (stopping) criteria (including requiring non-invasive permanent assisted ventilation support) are reached.</p><p>1.29.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered using the following age-appropriate scales: the Hammersmith Infant Neuromuscular Examination (HINE) Section 2, the Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) or Hammersmith Functional Motor Scale-Expanded (HFMSE) were appropriate scales for assessing motor function as per the proposed Special Authority criteria. </p><p>1.30.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the costs of providing paediatric intensive care support for patients requiring respiratory support needed to be included in the financial and economic analysis for the application; and that the costs derived from a German population, as cited in the application, were likely to be substantially lower than that in the New Zealand Health system. </p><p>1.31.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that, based on the epidemiological information provided, Māori did not appear to be disproportionately affected by SMA compared with the European population; however, the Committee considered that it was difficult to comment on this aspect given small patient numbers. </p><p>1.32.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that, for historical reasons, oncology paediatric patients have a different funding pathway for access to treatments compared with children with other serious illnesses and with adult patients. The Committee noted that nusinersen was not an oncology treatment and therefore considered it appropriate to consider nusinersen alongside all other pharmaceutical funding applications.</p>', 'Status_History__c': 'a132P000000BlFlQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jan 2022', 'fs': 'Jan 2022', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006tsaKUAQ'}, 'Id': 'a0P2P000006tsaKUAQ', 'Event_Date__c': '2022-01-28', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Jan 2022', 'Status_History__c': 'a132P000000DUwBQAW'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jan 2022', 'fs': 'Jan 2022', 'change': None}, 'Event_Description': {'s': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Thursday 17 February 2022', 'fs': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Thursday 17 February 2022', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006tsaLUAQ'}, 'Id': 'a0P2P000006tsaLUAQ', 'Event_Date__c': '2022-01-28', 'Event_Description__c': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Thursday 17 February 2022', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Jan 2022', 'Status_History__c': 'a132P000000DUwkQAG'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted that Pharmac was seeking further advice to inform its economic modelling of Spinal Muscular Atrophy (SMA) treatments, in particular the duration of treatment benefit to assume over a lifetime time horizon. The Committee noted that this a complex area with limited evidence to inform economic modelling.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee also noted that its views on the degree of treatment benefit associated with medicines in this area have been chronicled in previous meeting records, and informed by published evidence and New Zealand clinical expert advice. Consequently, the scope of this discussion was limited to the duration of that treatment benefit.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>To determine the appropriate duration of treatment effect, the Committee considered evidence relating to:</p><p class=""ql-indent-1"">1.3.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>the mechanism of action of medicines in this disease area,</p><p class=""ql-indent-1"">1.3.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>the duration of clinical evidence for the two medicines, and</p><p class=""ql-indent-1"">1.3.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>the strength of clinical evidence, including relationships between surrogate and final endpoints in this disease area and degree of evidenced treatment effect.</p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that there are two medicines currently under consideration for the treatment of SMA in New Zealand, nusinersen and risdiplam. The Committee noted that nusinersen and risdiplam have very similar mechanisms of action, and that there is high biological plausibility of an enduring treatment effect based on these mechanisms of action.</p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that currently nusinersen has longer-term follow up than risdiplam: the maximum length of results reported from phase three clinical trials are approximately 39 months for nusinersen and 24 months for risdiplam. The Committee considered that this length of evidence is relatively short for a life-long condition, and that the survival data in the clinical trials is extremely immature.</p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>However, the Committee also noted that the survival and progression free survival outcomes, in SMA type 1 especially, show substantial improvements relative to the natural history of disease. The degree of benefit in this group especially was considered persuasive in terms of the possible impact of the medicines in this area.</p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Members noted that SMA is somewhat different to other lifelong conditions in regard to the confidence with which assumptions can be made about long term impacts from available, short-term evidence. Members noted that relationships between surrogate markers and final endpoints (especially survival) have not been formally established in SMA to signal long term benefit, although evidence in this area may become available in the future.</p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that given the high biological plausibility of long term treatment effect and the extent of the treatment benefit, especially in SMA type 1, it was appropriate to assume that the duration of benefit from SMA treatments is lifelong, or for the duration of treatment, whichever is shorter. The Committee considered it appropriate to re-evaluate this view if more definitive evidence (eg validated surrogate outcomes, or long-term outcome data) became available.</p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the current recommended renewal criteria for ongoing treatment with the SMA treatments. The Committee considered that due to the difference between the renewal criteria and the stopping criteria in trials (ie ventilation), real world discontinuation rates in New Zealand would differ from discontinuation rates observed in the clinical trials, if nusinersen or risdiplam were funded in New Zealand with these renewal criteria.</p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that discontinuation of SMA treatment would be unlikely to change over time unless new treatments for SMA became available. The Committee also considered that the majority of people with SMA would be expected to continue treatment of some sort for as long as they lived, based on their physician’s ongoing evaluation of the benefit they were receiving, against the renewal criteria.</p><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered, despite the differences in SMA identified pre-symptomatically and symptomatically, that it would be appropriate to apply the same assumptions regarding a lifelong duration of treatment benefit to all groups. This was because the same arguments around biological plausibility were considered to apply to both subgroups, and the extent of benefit in the two groups has been evaluated and agreed separately.</p><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that based on previous consideration by PTAC and the Rare Disorders and Neurological Subcommittees, a large proportion of people with SMA would be assumed to have an SMA type 4 phenotype if treated in the pre-symptomatic setting. The Committee considered it important that the morbidity associated with an SMA type 4 phenotype be reflected in economic modelling in the decades after symptom onset with this phenotype, given the recommended assumption of lifelong benefit.</p><p>1.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee also considered that it would be appropriate for the same assumptions to be made for both nusinersen and risdiplam, noting that while data maturity differs between the two agents, the mechanisms of action and consequent biological plausibility of treatment effect are similar.</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted that Pharmac was seeking further advice to inform its economic modelling of Spinal Muscular Atrophy (SMA) treatments, in particular the duration of treatment benefit to assume over a lifetime time horizon. The Committee noted that this a complex area with limited evidence to inform economic modelling.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee also noted that its views on the degree of treatment benefit associated with medicines in this area have been chronicled in previous meeting records, and informed by published evidence and New Zealand clinical expert advice. Consequently, the scope of this discussion was limited to the duration of that treatment benefit.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>To determine the appropriate duration of treatment effect, the Committee considered evidence relating to:</p><p class=""ql-indent-1"">1.3.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>the mechanism of action of medicines in this disease area,</p><p class=""ql-indent-1"">1.3.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>the duration of clinical evidence for the two medicines, and</p><p class=""ql-indent-1"">1.3.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>the strength of clinical evidence, including relationships between surrogate and final endpoints in this disease area and degree of evidenced treatment effect.</p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that there are two medicines currently under consideration for the treatment of SMA in New Zealand, nusinersen and risdiplam. The Committee noted that nusinersen and risdiplam have very similar mechanisms of action, and that there is high biological plausibility of an enduring treatment effect based on these mechanisms of action.</p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that currently nusinersen has longer-term follow up than risdiplam: the maximum length of results reported from phase three clinical trials are approximately 39 months for nusinersen and 24 months for risdiplam. The Committee considered that this length of evidence is relatively short for a life-long condition, and that the survival data in the clinical trials is extremely immature.</p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>However, the Committee also noted that the survival and progression free survival outcomes, in SMA type 1 especially, show substantial improvements relative to the natural history of disease. The degree of benefit in this group especially was considered persuasive in terms of the possible impact of the medicines in this area.</p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Members noted that SMA is somewhat different to other lifelong conditions in regard to the confidence with which assumptions can be made about long term impacts from available, short-term evidence. Members noted that relationships between surrogate markers and final endpoints (especially survival) have not been formally established in SMA to signal long term benefit, although evidence in this area may become available in the future.</p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that given the high biological plausibility of long term treatment effect and the extent of the treatment benefit, especially in SMA type 1, it was appropriate to assume that the duration of benefit from SMA treatments is lifelong, or for the duration of treatment, whichever is shorter. The Committee considered it appropriate to re-evaluate this view if more definitive evidence (eg validated surrogate outcomes, or long-term outcome data) became available.</p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the current recommended renewal criteria for ongoing treatment with the SMA treatments. The Committee considered that due to the difference between the renewal criteria and the stopping criteria in trials (ie ventilation), real world discontinuation rates in New Zealand would differ from discontinuation rates observed in the clinical trials, if nusinersen or risdiplam were funded in New Zealand with these renewal criteria.</p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that discontinuation of SMA treatment would be unlikely to change over time unless new treatments for SMA became available. The Committee also considered that the majority of people with SMA would be expected to continue treatment of some sort for as long as they lived, based on their physician’s ongoing evaluation of the benefit they were receiving, against the renewal criteria.</p><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered, despite the differences in SMA identified pre-symptomatically and symptomatically, that it would be appropriate to apply the same assumptions regarding a lifelong duration of treatment benefit to all groups. This was because the same arguments around biological plausibility were considered to apply to both subgroups, and the extent of benefit in the two groups has been evaluated and agreed separately.</p><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that based on previous consideration by PTAC and the Rare Disorders and Neurological Subcommittees, a large proportion of people with SMA would be assumed to have an SMA type 4 phenotype if treated in the pre-symptomatic setting. The Committee considered it important that the morbidity associated with an SMA type 4 phenotype be reflected in economic modelling in the decades after symptom onset with this phenotype, given the recommended assumption of lifelong benefit.</p><p>1.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee also considered that it would be appropriate for the same assumptions to be made for both nusinersen and risdiplam, noting that while data maturity differs between the two agents, the mechanisms of action and consequent biological plausibility of treatment effect are similar.</p>', 'change': None}, 'Published_Application': {'s': '<p><span style=""color: rgb(68, 68, 68);"">The Committee reviewed the funding application for Nusinersen in the treatment of Spinal muscular atrophy Type I, II and III. The Committee took into account, where applicable, Pharmac&#39;s relevant decision-making framework when considering this agenda item</span></p>', 'fs': '<p><span style=""color: rgb(68, 68, 68);"">The Committee reviewed the funding application for Nusinersen in the treatment of Spinal muscular atrophy Type I, II and III. The Committee took into account, where applicable, Pharmac&#39;s relevant decision-making framework when considering this agenda item</span></p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'No Formal Recommendation', 'fs': 'No Formal Recommendation', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2022', 'fs': 'May 2022', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 17 February 2022.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 17 February 2022.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006tsaMUAQ'}, 'Id': 'a0P2P000006tsaMUAQ', 'Event_Date__c': '2022-05-13', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 17 February 2022.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'No Formal Recommendation', 'Formatted_Date__c': 'May 2022', 'Published_Application__c': '<p><span style=""color: rgb(68, 68, 68);"">The Committee reviewed the funding application for Nusinersen in the treatment of Spinal muscular atrophy Type I, II and III. The Committee took into account, where applicable, Pharmac&#39;s relevant decision-making framework when considering this agenda item</span></p>', 'Published_Discussion__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted that Pharmac was seeking further advice to inform its economic modelling of Spinal Muscular Atrophy (SMA) treatments, in particular the duration of treatment benefit to assume over a lifetime time horizon. The Committee noted that this a complex area with limited evidence to inform economic modelling.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee also noted that its views on the degree of treatment benefit associated with medicines in this area have been chronicled in previous meeting records, and informed by published evidence and New Zealand clinical expert advice. Consequently, the scope of this discussion was limited to the duration of that treatment benefit.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>To determine the appropriate duration of treatment effect, the Committee considered evidence relating to:</p><p class=""ql-indent-1"">1.3.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>the mechanism of action of medicines in this disease area,</p><p class=""ql-indent-1"">1.3.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>the duration of clinical evidence for the two medicines, and</p><p class=""ql-indent-1"">1.3.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>the strength of clinical evidence, including relationships between surrogate and final endpoints in this disease area and degree of evidenced treatment effect.</p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that there are two medicines currently under consideration for the treatment of SMA in New Zealand, nusinersen and risdiplam. The Committee noted that nusinersen and risdiplam have very similar mechanisms of action, and that there is high biological plausibility of an enduring treatment effect based on these mechanisms of action.</p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that currently nusinersen has longer-term follow up than risdiplam: the maximum length of results reported from phase three clinical trials are approximately 39 months for nusinersen and 24 months for risdiplam. The Committee considered that this length of evidence is relatively short for a life-long condition, and that the survival data in the clinical trials is extremely immature.</p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>However, the Committee also noted that the survival and progression free survival outcomes, in SMA type 1 especially, show substantial improvements relative to the natural history of disease. The degree of benefit in this group especially was considered persuasive in terms of the possible impact of the medicines in this area.</p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Members noted that SMA is somewhat different to other lifelong conditions in regard to the confidence with which assumptions can be made about long term impacts from available, short-term evidence. Members noted that relationships between surrogate markers and final endpoints (especially survival) have not been formally established in SMA to signal long term benefit, although evidence in this area may become available in the future.</p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that given the high biological plausibility of long term treatment effect and the extent of the treatment benefit, especially in SMA type 1, it was appropriate to assume that the duration of benefit from SMA treatments is lifelong, or for the duration of treatment, whichever is shorter. The Committee considered it appropriate to re-evaluate this view if more definitive evidence (eg validated surrogate outcomes, or long-term outcome data) became available.</p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the current recommended renewal criteria for ongoing treatment with the SMA treatments. The Committee considered that due to the difference between the renewal criteria and the stopping criteria in trials (ie ventilation), real world discontinuation rates in New Zealand would differ from discontinuation rates observed in the clinical trials, if nusinersen or risdiplam were funded in New Zealand with these renewal criteria.</p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that discontinuation of SMA treatment would be unlikely to change over time unless new treatments for SMA became available. The Committee also considered that the majority of people with SMA would be expected to continue treatment of some sort for as long as they lived, based on their physician’s ongoing evaluation of the benefit they were receiving, against the renewal criteria.</p><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered, despite the differences in SMA identified pre-symptomatically and symptomatically, that it would be appropriate to apply the same assumptions regarding a lifelong duration of treatment benefit to all groups. This was because the same arguments around biological plausibility were considered to apply to both subgroups, and the extent of benefit in the two groups has been evaluated and agreed separately.</p><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that based on previous consideration by PTAC and the Rare Disorders and Neurological Subcommittees, a large proportion of people with SMA would be assumed to have an SMA type 4 phenotype if treated in the pre-symptomatic setting. The Committee considered it important that the morbidity associated with an SMA type 4 phenotype be reflected in economic modelling in the decades after symptom onset with this phenotype, given the recommended assumption of lifelong benefit.</p><p>1.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee also considered that it would be appropriate for the same assumptions to be made for both nusinersen and risdiplam, noting that while data maturity differs between the two agents, the mechanisms of action and consequent biological plausibility of treatment effect are similar.</p>', 'Status_History__c': 'a132P000000Dkm4QAC'}, 'change': None}]",Sep 2018,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2020', 'fs': 'Feb 2020', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006tsaFUAQ'}, 'Id': 'a0P2P000006tsaFUAQ', 'Event_Date__c': '2020-02-26', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Feb 2020', 'Status_History__c': 'a132P000000BVR0QAO'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2022', 'fs': 'May 2022', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006tsaNUAQ'}, 'Id': 'a0P2P000006tsaNUAQ', 'Event_Date__c': '2022-05-17', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'May 2022', 'Status_History__c': 'a132P000000DlL3QAK'}, 'change': None}]",Feb 2020,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Apr 2020', 'fs': 'Apr 2020', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006tsaGUAQ'}, 'Id': 'a0P2P000006tsaGUAQ', 'Event_Date__c': '2020-04-16', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Apr 2020', 'Status_History__c': 'a132P000000BgHiQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2020', 'fs': 'Jun 2020', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006tsaIUAQ'}, 'Id': 'a0P2P000006tsaIUAQ', 'Event_Date__c': '2020-06-23', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Jun 2020', 'Status_History__c': 'a132P000000BtQmQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2020', 'fs': 'Dec 2020', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006tsaJUAQ'}, 'Id': 'a0P2P000006tsaJUAQ', 'Event_Date__c': '2020-12-16', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Dec 2020', 'Status_History__c': 'a132P000000CSGeQAO'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2022', 'fs': 'Jun 2022', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006tsaOUAQ'}, 'Id': 'a0P2P000006tsaOUAQ', 'Event_Date__c': '2022-06-02', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Jun 2022', 'Status_History__c': 'a132P000000DnXuQAK'}, 'change': None}]",Apr 2020,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-09-28-proposal-to-fund-nusinersen-spinraza-for-spinal-muscular-atrophy/"" target=""_blank"">Consultation letter</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-09-28-proposal-to-fund-nusinersen-spinraza-for-spinal-muscular-atrophy/"" target=""_blank"">Consultation letter</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Sep 2022', 'fs': 'Sep 2022', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006tsaPUAQ'}, 'Id': 'a0P2P000006tsaPUAQ', 'Event_Date__c': '2022-09-28', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-09-28-proposal-to-fund-nusinersen-spinraza-for-spinal-muscular-atrophy/"" target=""_blank"">Consultation letter</a></p>', 'Formatted_Date__c': 'Sep 2022', 'Status_History__c': 'a132P000000E4hfQAC'}, 'change': None}]",Sep 2022,False,True
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Oct 2022', 'fs': 'Oct 2022', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006tsaQUAQ'}, 'Id': 'a0P2P000006tsaQUAQ', 'Event_Date__c': '2022-10-24', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Formatted_Date__c': 'Oct 2022', 'Status_History__c': 'a132P000000ED7jQAG'}, 'change': None}]",Oct 2022,False,True
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-12-08-nusinersen-spinraza-notification/"" target=""_blank"">Notification letter</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-12-08-nusinersen-spinraza-notification/"" target=""_blank"">Notification letter</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Dec 2022', 'fs': 'Dec 2022', 'change': None}, 'Event_Description': {'s': 'The funding application has been approved.', 'fs': 'The funding application has been approved.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006tsaRUAQ'}, 'Id': 'a0P2P000006tsaRUAQ', 'Event_Date__c': '2022-12-08', 'Event_Description__c': 'The funding application has been approved.', 'Stage__c': 'Decision', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-12-08-nusinersen-spinraza-notification/"" target=""_blank"">Notification letter</a></p>', 'Formatted_Date__c': 'Dec 2022', 'Status_History__c': 'a132P000000ED8NQAW'}, 'change': None}]",Dec 2022,False,True
